• Home
  • Topics
    • Health Insurance Coverage
    • Medicare
    • Medicaid and CHIP
    • Blue Cross Blue Shield
    • Health Insurance Companies
    • Prescription Drugs and Pharmacy
    • Healthcare Policy and Law
    • Hospitals and Health Systems
    • Healthcare Business
    • Health Technology and AI
    • Senior Care
    • Public Health and Research
  • Guides
    • All Health Insurance Guides
    • Choosing a Health Insurance Plan
    • Individual Health Insurance
    • Family Health Insurance
    • High Deductible Health Plans
    • Short-Term Health Insurance
    • Self-Employed Health Insurance
    • Student Health Insurance
    • Low Income Health Insurance
    • Health Sharing Plans
  • Insurance Company List
  • About Us

Health Plan News

Timely Health Plan News and Commentary

Health Plan News
Home Archives for Hospitals and Health Systems

Hospitals and Health Systems News

Hospitals and health systems are where most health care dollars are spent, and the relationship between providers and health plans determines which facilities are in network and what patients pay. A health system is an organization that owns or operates multiple hospitals, physician practices, clinics and outpatient centers under common management, such as nonprofit systems like UnityPoint Health and academic medical centers like Cincinnati Children's.

What We Cover

This section covers hospital and health system strategy, expansions and closures, contract negotiations and network disputes with insurers, quality and patient safety ratings, staffing and workforce issues, physician group news, clinical programs, and community health investments. We also report on revenue cycle operations, the billing and collections work behind every patient account, and on the outsourcing and automation that systems are adopting to control administrative costs.

Provider news intersects with nearly every other part of the health plan business. When a health system and a carrier cannot agree on rates, members may lose in-network access; those disputes involve the companies covered in Health Insurance Companies and Blue Cross Blue Shield. Mergers, acquisitions and leadership appointments among providers are covered in Healthcare Business. Technology adopted by hospitals, including artificial intelligence (AI) in clinical and administrative workflows, appears in Health Technology and AI. Patient safety litigation and regulatory action appear in Healthcare Policy and Law, and skilled nursing and home health providers are covered in Senior Care.

The latest hospital and health system news appears below, newest first.

MedLink and Thrasys Announce Formation of the New York Health Information Network

Posted on October 21, 2010 Written by Editor

SOURCE: MedLink International, Inc.

NEW YORK, NY–(Marketwire – October 21, 2010) –  MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions to the medical community announced today the formation of the New York Health Information Network as a collaboration with Thrasys, Inc. a provider of next-generation health information technology and solutions. The New York Health Information Network (NYHIN) will be the first of many regional health information networks to be deployed by MedLink and Thrasys under a Connected Healthcare initiative launched by the two companies earlier this year. Connected Healthcare and regional health information networks will enable communities of physicians, patients, service centers, and health plans to coordinate care, manage costs, increase revenues, improve outcomes and enhance patient experience.

The New York Health Information Network will provide interoperability, applications and services using the cloud-based SyntraNet connected healthcare platform from Thrasys. SyntraNet provides an open foundation for highly scalable collaborative healthcare networks. The New York Health Information Network will implement a health information exchange to meet interoperability requirements for ‘Meaningful Use’ and deliver a range of applications and services: electronic health records, practice management services, e-prescribing, group purchasing, insurance and eligibility verification, remote charge capture, physician quality reporting, patient portals, and services to enable accountable care organizations and patient medical homes.

Ramesh Balakrishnan, CEO of Thrasys, stated, “The New York Health Information Network is a first step in our vision to use disruptive technologies to enable a new model for collaborative care. Our goal with Connected Healthcare is to evolve an open healthcare platform that provides core interoperability, applications and services and also enables third-parties and partners to offer a range of add-on solutions. This kind of open, connected and collaborative technology platform is the necessary foundation to support initiatives currently underway to coordinate care, improve outcomes and manage costs. With more than $500m in HITECH funding for HIE initiatives, we will continue to partner with communities of physicians, hospitals, service center, and health plans to implement showcases for the future of healthcare.”

Ray Vuono, CEO of MedLink, continued, “The Health information Network provides a financial benefits for the NYHIN partners including Providers, establishing a revenue model through member based services for as little as $500 per member annually. The products and services are provided by healthcare vendors and service providers that leverage the platform to provide their services to HIN population of physicians, medical facilities, and patients; providing a Web 2.0 healthcare super highway income model similar to that of the iPhone Apps marketplace or Salesforce.com.”

Scott Einiger, Senior Partner at Abrams Fensterman, a leading New York healthcare law firm, commented, “The New York Health Information Network will enable physicians to level the playing field and have access to core health care products and services critical to success in this rapidly evolving healthcare landscape. As physicians join this Network, the quality of the products and services will expand exponentially making available the best of breed applications and services due to substantial Vendor commitment to grow within the Network. I expect this network to grow beyond NY State and become a nationally connected Network enuring to the benefit of patients and physicians alike and greatly enhancing our federal government’s health law reform initiative.”

About MedLink

MedLink is a healthcare IT company that provides the medical community with products and services designed to help create, manage, and share medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-K available through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Jameson Rose
(631) 342-8800
Email Contact

Filed Under: Health Technology and AI, Hospitals and Health Systems

Helix BioPharma Corp. Reports Positive Efficacy and Safety Findings From Phase II Study of Its Topical Interferon Alpha-2b in Patients With Low-Grade…

Posted on October 21, 2010 Written by Editor

SOURCE: Helix BioPharma Corp.

After Treatment, 71.4% of the Women No Longer Had Potentially Pre-Cancerous Low-Grade CIN 1 or CIN 2 Cervical Lesions

AURORA, ON–(Marketwire – October 21, 2010) –  Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced positive efficacy and safety findings from its recently completed Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. These findings build upon the positive pharmacokinetic findings from this study announced in the Company’s press release of June 23, 2010.

Using colposcopic directed biopsy to determine the treatment’s effectiveness, 71.4% of the women in the study no longer had potentially pre-cancerous, low-grade lesions known as cervical intraepithelial neoplasia grade 1 or 2 (CIN 1 or CIN 2) following treatment. Colposcopic directed biopsy is generally considered the leading method for diagnosing potential cervical precancer today. In addition, Topical Interferon Alpha-2b demonstrated an excellent safety profile, with no significant local intolerance findings and no serious adverse events.

There are approximately 1.3 million women diagnosed with CIN 1 or CIN 2 lesions each year in the U.S. alone. Currently, there are no pharmaceutical (non-surgical) treatments for these women. Available invasive/surgical techniques to treat CIN 1 or CIN 2 lesions are sometimes associated with serious unwanted side effects for patients, including cervical complications with pregnancy and conception. Accordingly, available invasive/surgical techniques are generally utilized only in the case of many months of long-term persistence and/or progression of CIN 1 or CIN 2 lesions, leaving patients uncertain and anxious about their prognosis in the interim.

“We are pleased with these findings because they provide further evidence of the potential effectiveness of Topical Interferon Alpha-2b for treating women with potentially precancerous, low-grade cervical lesions,” said John Docherty, president of Helix BioPharma Corp. “These findings suggest that Topical Interferon Alpha-2b could offer women a safe and immediate therapeutic alternative to today’s protracted observational and potentially problematic surgical approach to managing this disease. We are now awaiting approval by the U.S. Food and Drug Administration of our application to conduct an expanded U.S. Phase II/III randomized, double-blind, controlled, pivotal efficacy trial in patients with low-grade cervical lesions.”

The study also examined Papanicolaou (“Pap”) smear response rate as a secondary efficacy parameter in the patients. The finding was less pronounced with 35.7% of the women demonstrating resolution of their abnormal Pap smears. However, this study was specifically designed with a relatively short post-treatment follow-up period as it was principally intended to provide pharmacokinetic results. The Company was, therefore, not surprised by this finding. By comparison, the Company has previously reported a more pronounced Pap response rate in patients treated with Topical Interferon Alpha-2b when it employed a longer post-treatment follow-up period.

About the Clinical Study

The clinical study employed an open-label, single-arm design and enrolled a total of 14 female patients with low-grade cervical lesions. Eligible women were between 18 and 45 years of age, presented with mild to moderate CIN (CIN1 or CIN2 respectively) confirmed by biopsy/histology, had a cytological diagnosis of Pap IIID not older than 12 months and were human papillomavirus (HPV)-positive confirmed by the Hybrid Capture® 2 HPV-DNA test. The primary objective of the study was to determine the multiple-dose pharmacokinetic profile of Topical Interferon Alpha-2b following intravaginal application every other day of a total of 14 doses of the cream. Helix previously announced on June 23, 2010 that all 14 patients were found to have circulating interferon alpha-2b levels below the bioassay lower limit of detection (6.25 pg/mL) at all sampling time points. Following the pharmacokinetic portion of the trial, assessment of the secondary efficacy and safety parameters continued until 35 doses of the cream were applied. As such, the clinical study was designed to also mimic the dosing regimen intended to be applied in Helix’s planned U.S. Phase II/III and European Phase III pivotal efficacy trials for this indication. The clinical study was conducted under the direction of Prof. Dr. med. Achim Schneider, M.P.H., a world expert in the field of cervical cancer and Director of the Department of Gynecology at the Charité University Hospital in Berlin, Germany.

About CIN 1 and CIN 2

CIN 1 and CIN 2 are potentially precancerous, low-grade cervical lesions detectable upon colposcopic directed biopsy. There are approximately 1.3 million women diagnosed with CIN 1 or CIN 2 lesions each year in the U.S. alone, according to data from 2006 Consensus Guidelines in the American Journal of Obstetrics and Gynecology 2007; 340-345 and Kaiser Permanente Northwest Health Plan in the American Journal of Obstetrics and Gynecology (2004) 191, 105-13. Currently there are no pharmaceutical (non-surgical) treatments for women with CIN 1 or CIN 2 lesions. Available invasive/surgical techniques to treat CIN 1 or CIN 2 lesions are sometimes associated with serious unwanted side effects for patients including cervical complications with pregnancy and conception. For patients with CIN 1 or CIN 2 lesions, clinical management usually consists of protracted watchful waiting with frequent Pap smears, HPV testing, colposcopy and/or colposcopic directed biopsies, with invasive/surgical techniques generally utilized only in the case of long-term persistence and/or progression after a period of many months. A diagnosis of CIN 1 or CIN 2 leads to frequent physician visits, procedures, and psychosocial stress for the patient. The goal of developing Topical Interferon Alpha-2b is to provide a safe and effective treatment for CIN 1 or CIN 2 at the time of diagnosis, as a proactive alternative to today’s often protracted observational management approach.

About Topical Interferon Alpha-2b

Interferon alpha-2b is a potent cytokine that possesses antiviral, immunomodulatory and antiproliferative activities with activity against HPV. Topical Interferon Alpha-2b is a semi-solid formulation of recombinant interferon alpha-2b based on Helix’s Biphasix™ platform drug formulation technology. This technology involves the formation of biphasic lipid vesicles for use as a vehicle for administration of a biologically active material encapsulated within the lipid bilayers. Topical Interferon Alpha-2b has been developed as a cosmetically appealing cream dosage form that can be easily and conveniently self-applied intravaginally for the treatment of low-grade cervical lesions using a common vaginal applicator.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and FSE under the symbol “HBP”. For more information, please visit www.helixbiopharma.com.

Forward-Looking Statements and Risks and Uncertainties

This News Release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”), within the meaning of applicable securities laws, regarding the Company’s plans for the development of Topical Interferon Alpha-2b in patients with low grade cervical lesions; the effectiveness of Topical Interferon Alpha-2b and its role as a therapeutic alternative; its planned designs for such proposed trial as well as its proposed European Phase III clinical trial; the development of Helix’s L-DOS47 and Topical Interferon Alpha-2b new drug candidates; and other information in future periods. Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions which have been applied in making such forward-looking statements, include, but are not limited to, assumptions regarding the safety and efficacy of Helix’s drug candidates; the timely receipt of necessary regulatory approvals and appropriate financing and strategic partner support; the timely and successful completion of the proposed U.S. and European clinical trials; and that the Company’s drug candidates will ultimately be successfully developed and commercialized. Important risk factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, that the Company’s assumptions may prove to be incorrect; the Company’s continuing need for additional capital and for substantial funding beyond its current resources, as well as strategic partner support, to conduct the proposed U.S. and European trials, which are not assured; regulatory approvals to conduct the planned U.S. and European trials may be delayed or denied; the fact that results in earlier clinical studies may not be repeated in later clinical trials, and one or both of the planned clinical trials could fail; the failure of the European trial could have a material adverse impact on the U.S. trial and FDA approval; the need for further regulatory approvals, which are not assured; the Company’s dependence on performance by its third party providers of intellectual property, services and supplies, including without limitation, clinical trial services and supplies of drug product; the risk that Helix’s supplier of interferon alpha-2b may not continue to provide necessary supplies or exercise its commercialization option; the risk that the design or duration, or both, of the planned clinical trials may be different than currently intended; the potential need for further clinical trials beyond those mentioned in this news release which may not occur as planned or achieve expected results; product liability and insurance risks; risks and uncertainties related to research and development, including clinical trial and manufacturing risks; intellectual property risks, including without limitation, the risk that three patents for Topical Interferon Alpha-2b will expire in 2013 and no additional patent may be issued, which may negatively impact the further development or commercialization of the drug candidate; the effect of competition and the fact that there are a number of other companies developing potentially competitive products; uncertainties related to economic conditions; uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be successfully developed and commercialized; exchange rate risk; and the risk of changes in business strategy or development plans. Investors should consult the Company’s quarterly and annual filings, including its latest Form 20-F, with the Canadian and U.S. securities commissions at www.sedar.com and at www.sec.gov for additional information on these and other risks and uncertainties which may affect the Company. Investors are cautioned against placing undue reliance on forward-looking statements. Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix’s management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, assumptions, opinions or expectations change, except as required by securities law.

Filed Under: Hospitals and Health Systems, Public Health and Research

SOUTHERN SURGICAL HOSPITAL Has Been Designated as a Blue Distinction Center for Bariatric Surgery(R)

Posted on October 20, 2010 Written by Editor

SOURCE: Southern Surgical Hospital

Blue Distinction Centers for Bariatric Surgery®

SLIDELL, LA–(Marketwire – October 20, 2010) –  Blue Cross and Blue Shield of LOUISIANA has designated SOUTHERN SURGICAL HOSPITAL as a Blue Distinction Center for Bariatric Surgery. To date, more than 230 facilities nationwide have received a Blue Distinction Center for Bariatric Surgery designation.

Obesity is widely recognized as a contributor to serious health risks. According to the Agency for Healthcare Research and Quality (AHRQ), the total number of bariatric surgeries increased 400 percent from 1998 to 2004. Bariatric surgery may help some individuals reduce extreme obesity and its associated health risks, and Blue Distinction provides objective information to help them make informed decisions when choosing a provider.

“SOUTHERN SURGICAL HOSPITAL is proud to receive this distinction from Blue Cross/Blue Shield. We look forward to providing our high level of surgical weight loss services to the Blue Cross/Blue Shield community,” said Michael J Thomas MD, Medical Director Bariatric Program, Southern Surgical Hospital.

SOUTHERN SURGICAL HOSPITAL provides a full range of bariatric surgery care services, including inpatient care, post-operative care, outpatient follow-up and patient education.

Blue Distinction puts a high value on research and evidence-based health and medical information,” says Allan Korn, MD, Blue Cross and Blue Shield Association Chief Medical Officer. “Blue Distinction Centers show our commitment to working with doctors and hospitals in communities across the country to identify leading institutions that meet clinically validated quality standards and deliver better overall outcomes in patient care.”

To be designated as a Blue Distinction Center for Bariatric Surgery, SOUTHERN SURGICAL HOSPITAL met the selection criteria posted at www.BCBS.com, which includes:

  • an established bariatric surgery program, actively performing these procedures for the most recent 12-month period and performing a required minimum volume of 125 such surgeries annually
  • appropriate experience of its bariatric surgery team
  • an acute care inpatient facility, including intensive care and emergency services
  • full accreditation by The Joint Commission, Healthcare Facilities Accreditation Program (HFAP) or national equivalent**
  • a comprehensive quality management program

Blue Distinction is a designation awarded by Blue Cross and Blue Shield companies to medical facilities that have demonstrated expertise in delivering quality healthcare. The designation is based on rigorous, evidence-based selection criteria established in collaboration with expert physicians’ and medical organizations recommendations.

Today, more than 800 Blue Distinction Center designations have been awarded to facilities nationwide, providing consumers with a framework for making informed decisions on where to go for specialty care in the areas of bariatric surgery, cardiac care, complex and rare cancers, and transplants.

**Note: Designation as Blue Distinction Centers means these facilities’ overall experience and aggregate data met objective criteria established in collaboration with expert clinicians’ and leading professional organizations’ recommendations. Individual outcomes may vary. To find out which services are covered under your policy at any facilities, please call your local Blue Cross and/or Blue Shield Plan.

Contact:
Anne Tucker
Direct 985.661.2135
Fax 985.661.2136
Email Contact

Filed Under: Blue Cross Blue Shield, Hospitals and Health Systems

ESi Becomes an Authorized Provider of IACET Continuing Education Units

Posted on October 20, 2010 Written by Editor

SOURCE: ESi

AUGUSTA, GA–(Marketwire – October 20, 2010) –  The International Association for Continuing Education and Training (IACET) has awarded ESi® its prestigious Authorized Provider status. IACET Authorized Providers are the only organizations approved to offer IACET continuing education units (CEUs). The recognition period extends for five years and includes all programs offered or created during that time.

“ESi education programs train thousands of emergency management professionals each year in the proper use and administration of our full suite of crisis information management products, including WebEOC®, WebEOC Mapper, and ESiWebFUSION™,” said Jim Cook, President of ESi University. “Our new partnership with IACET is a demonstration of our commitment to lifelong learning and high standards for all of our programs, and we are very pleased to join such a prestigious organization.”

“We are pleased to welcome ESi as our newest Authorized Provider organization,” said Karen Brown, President of IACET and Senior HR Manager of Nuclear Power at Shaw Group in Massachusetts. “ESi joins nearly 650 organizations around the globe that have had their programs vetted by third-party experts in continuing education to ensure the highest possible standards are met.”

ESi University develops and delivers training courses to ESi customers throughout the world at its state-of-the-art training facility in Atlanta, through its e-learning portal, and via its virtual classroom which allows students and instructors to see and hear each other and share computer screens during courses.

In order to achieve Authorized Provider status, ESi completed a rigorous application process, including a review by an IACET site visitor and successfully demonstrated adherence to the ANSI/IACET 1-2007 Standard addressing the design, development, administration, and evaluation of its programs. ESi has pledged to continue its compliance with the Standard and is now authorized to use the IACET name and Authorized Provider logo on promotional course material. In addition, ESi is now linked to the IACET web site and is recognized as offering the highest quality continuing education and training programs.

About ESi
Augusta, Georgia-based ESi®, the global leader in crisis information management technology, pioneered the market with WebEOC®, the world’s first Web-enabled emergency management communications system. Recognized by Inc. Magazine as one of the fastest-growing private companies in America from 2007 through 2010, ESi connects crisis response teams and decision makers at national, state and local agencies, healthcare providers, airlines and corporations worldwide, providing access to real-time information for a common operating picture during a crisis or daily operations. By offering a solutions package from initial design and installation through training, implementation, and maintenance, ESi sets the standard for crisis information management. For more information, please visit www.ESi911.com.

About IACET
The International Association for Continuing Education and Training (IACET) is a non-profit association dedicated to quality continuing education and training programs. IACET is the only standard-setting organization approved by the American National Standards Institute (ANSI) for continuing education and training. The ANSI/IACET 1-2007 Standard is the core of thousands of educational programs worldwide. For more information, please visit www.iacet.org or call 703-506-3275.

Contact:
Anne Murray Sims
ESi
706.262.2686

Click here to see all recent news from this company

Filed Under: Hospitals and Health Systems

Veterans Find Healing and Hope Through Creative Arts Festival

Posted on October 20, 2010 Written by Editor

SOURCE: Help Hospitalized Veterans

WINCHESTER, CA–(Marketwire – October 20, 2010) –  For many of the talented veterans participating in the National Veterans Creative Arts Festival this year in Tomah, Wisconsin, the interest in art as therapy came about during a Department of Veterans Affairs (VA) hospital stay. VA utilizes a unique rehabilitation treatment component which often includes exposing veteran patients to a variety of creative healing opportunities.

With humble beginnings in 1981 as two separate competitions: “Vet Arts” in Richmond, Virginia and “The National Music Competition for Veterans” in Waco, Texas, the annual Festival is now a popular national event showcasing the artistic achievements of veterans from across the nation. The roughly 130 veterans invited to the Festival this year are winners of fine arts and talent competitions in which thousands of veterans have entered. The event is a celebration of achievements in art, creative writing, dance, drama and original writing with a gala variety show featuring a professional orchestra.

“The National Veterans Creative Arts Festival is an exciting event. The intricate, original artwork and incredible performance talent displayed is outstanding,” said Mike Lynch, president and CEO of Help Hospitalized Veterans (HHV) an event co-sponsor. “The therapeutic benefits veterans receive from participating is highly evident. The stage show is first-class and features our nation’s top veteran performers and the craftwork displayed during the art exhibit is breathtaking,” said Lynch. The Festival takes place on Sunday, October 24, 2010 at the Viterbo University Fine Arts Center in La Crosse, Wisconsin. The art exhibit opens at 12:15 p.m. and the stage show begins at 2:00 p.m. Admission is free, but a ticket is required for the stage show.

Since 1971, HHV has donated over 28 million free arts & crafts and other products and services to VA and military hospitals worldwide. For more information visit www.hhv.org or call 1-888-567-VETS.

Documents and/or Photos available for this release:

PDF_of_release

To view supporting documents and/or photos, go to www.enr-corp.com/pressroom and enter Release ID: 274935

Filed Under: Hospitals and Health Systems

Bosch Health Buddy(R) Telehealth System Programs Receive Certification From the National Committee for Quality Assurance

Posted on October 20, 2010 Written by Editor

SOURCE: Robert Bosch Healthcare

PALO ALTO, CA–(Marketwire – October 20, 2010) –  

  • Independent review board commends system’s design and performance
  • Thirteen programs earn disease management certification status
  • Company leads telehealth industry in certification 

Robert Bosch Healthcare, Inc., a leader in telehealth systems, announced today that it received recertification in Disease Management (DM) from the National Committee for Quality Assurance (NCQA) for ten of its Health Buddy® System Health Management programs, and new certification for three additional programs. All 13 Health Management programs are administered through the Health Buddy System, which serves as an interface between at-home chronically ill patients and their care providers, facilitating remote monitoring of patient health status and promoting patient education and self-care.

“NCQA DM certification demonstrates that an organization is well suited to deliver programs to manage care for the seriously or chronically ill. As it’s a difficult test, it says a lot that an organization is willing to step forward to be reviewed,” said NCQA Executive Vice President, Greg Pawlson, M.D.

NCQA certification is a comprehensive and transparent evaluation through which the quality of the systems, processes and results that define a health plan is assessed. After evaluations are conducted by physicians and/or experts in the product evaluated, an oversight committee analyzes the findings and assigns a score based on the applicant’s performance against NCQA’s standards. Robert Bosch Healthcare received a score of 100%, based on its overall submissions. Each certification is valid for two years.

Bosch leads the industry in its number of NCQA certifications. Ten Health Buddy System Health Management Programs recertified are: Asthma, Cancer, Cardiovascular Disease, Congestive Heart Failure, Chronic Pain, Chronic Obstructive Pulmonary Disease (COPD), Depression, Diabetes, Hypertension and Pediatric Asthma. New programs receiving certification for the first time are: Diabetes/Hypertension, Heart Failure/Diabetes and Renal Disease.

These programs scored high in each element of the DM certification for Program Design. Evaluation criteria includes the use of evidence-based guidelines or standards of care in program development, consistency of content with adopted guidelines, and development of patient information that assists with self-management. NCQA noted specific strengths of the Health Buddy System: the large array of disease programs offered; the branching logic applied to the patient question and answer “dialogues”; and Bosch Healthcare’s process for tracking and changing content as guidelines change. Also noted was the use of health dialogues to gather an extensive amount of patient data, in order to identify and address patient safety issues. The risk stratification of safety alerts allows immediate review of information by a clinician.

“The rigorous, independent review taken by NCQA underlines the high quality standards and demonstrated effectiveness of the Health Buddy System in improving care for patients with chronic conditions,” said Derek Newell, President Robert Bosch Healthcare. “Each day, around 30,000 patients connect to their care providers using the Health Buddy System. Customers can be assured that our Health Management Programs are based on sound clinical principles and standard guidelines, which ultimately enable care providers to better support chronically ill patients without increasing costs.”

About the Bosch Healthcare Health Buddy System
In use for more than ten years, the Health Buddy System includes a compact device that patients use at home to answer a series of questions about their health and symptoms, and receive information that helps them better manage their chronic conditions. Patient data gathered by the device is transmitted to a secure data center and quickly risk-stratified, giving proactive providers the opportunity to intervene before the patient’s condition becomes critical. 

About the National Committee for Quality Assurance
The National Committee for Quality Assurance (NCQA) is a non-profit organization dedicated to improving health care quality. Since its founding in 1990, NCQA has been a central figure in driving improvement throughout the health care system. Through its certification review process, NCQA certifies a wide range of health care organizations and programs. Its disease management certification standards are intended to reduce patient risk, help organizations achieve the highest level of performance possible, and create an environment of continuous improvement. For more information, visit www.ncqa.org.

About The Bosch Group:

Robert Bosch Healthcare Inc. is a leading provider of innovative telehealth systems. Bosch’s product spectrum ranges from patient terminals to comprehensive evaluation software allowing healthcare professionals to efficiently evaluate the data coming from the patient terminals and other connected devices. Bosch Telehealth strives to improve diagnosis and treatment through systematic patient monitoring and involvement. The result is that health professionals are able to provide a higher quality of care for patients with chronic conditions, patients lead happier and healthier lives, and the cost of healthcare is reduced for funders. Robert Bosch Healthcare, Inc. is a fully-owned subsidiary of the Bosch Group. For more information, go to www.bosch-telehealth.com.

The Bosch Group is a leading global supplier of technology and services. In the areas of automotive and industrial technology, consumer goods, and building technology, some 275,000 associates generated sales of 38.2 billion euros (roughly $53 billion) in fiscal 2009. The Bosch group comprises Robert Bosch GmbH and its more than 300 subsidiaries and regional companies in over 60 countries. This worldwide development, manufacturing, and sales network are the foundation for growth. Each year, Bosch spends more than 3.5 billion euros ($5 billion) for research and development, and applies for some 3,800 patents worldwide. With all its products and services, Bosch works to enhance the quality of life by providing solutions which are both innovative and beneficial. For more information, visit www.bosch.com.

In the U.S., Canada and Mexico, the Bosch Group manufactures and markets automotive original equipment and aftermarket products, industrial drives and control technology, power tools, security and communication systems, packaging technology, thermotechnology, household appliances, solar energy and healthcare products. Having established a regional presence in 1906, Bosch employs over 20,000 associates in more than 70 locations, with reported sales of $7.3 billion in fiscal 2009. For more information, visit www.boschusa.com.

National Committee for Quality Assurance
Celebrating its 20th anniversary in 2010, NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care. NCQA is committed to providing health care quality information for consumers, purchasers, health care providers, and researchers. 

Contact:
Edie DeVine
phone: +1-415-365-8543

Click here to see all recent news from this company

Filed Under: Health Technology and AI, Hospitals and Health Systems

SANYO Introduces Industry’s First Stand-Alone Cell Processing Work Station Transforming the Biomedical Cleanroom

Posted on October 20, 2010 Written by Editor

SOURCE: SANYO

Introduction Makes SANYO a Leading Player in Equipping the Stem Cell Therapy Industry

WOOD DALE, IL–(Marketwire – October 20, 2010) –  SANYO North America Corporation (SANYO) announces that its Biomedical Solutions Division is moving to the forefront of the stem cell and cell therapy market with the introduction of the industry’s first integrated, stand-alone Cell Processing Work Station (CPWS), becoming a significant solutions provider in this high growth, high opportunity marketplace. Offering a turnkey and standalone solution, SANYO’s CPWS is an innovative, cost effective and space-saving solution for the GMP compliant processing and manufacture of regenerative stem cell and cell therapies. The CPWS lowers barriers to enter the cell therapeutics market, positively impacting both public and private institutions. The workstation provides the required class-100 aseptic environment, but in a compact and less expensive than a traditional costly and large footprint cleanroom.

The cell therapy market is increasingly playing an important role in the practice of medicine, and the number of companies and entities that are involved in cell therapy are on the rise, including academic institutions and public and private companies. The market is expected to expand over the next decade, with applications for the technology to include cancer, cardiac and genetic disorders as well as wounds of the skin and soft tissues.

“SANYO is prepared to expand into this rapidly growing market with its new Cell Processing Work Station, which will provide a practical solution for its biotech and pharmaceutical customers to develop and manufacture advanced cell therapies and hospitals to develop cell therapies for use in clinical trials,” stated Ron Dudek, New Business Development Manager.

The CPWS is a stand-alone, alternative to a traditional cleanroom, and the station is a self-contained system with a small footprint that is quick and easy to install. Offering a highly efficient operational capacity and featuring a contamination-free design, the workstation includes cGMP compliant equipment for aseptic processing and provides user-friendly operation. The SANYO CPWS also saves approximately 35% of the operating costs usually required for conventional cleanrooms (open systems).

The CPWS significantly lowers barriers to entry to the cell therapeutics market, which will impact both the private and public institutions within the life science, clinical, biotechnology and pharmaceutical markets. Current and future applications of the CPWS include regenerative organ development, and tissue regeneration such as skin, cartilage, alveolar bone, cornea, cardiac muscle, nerve, liver and pancreas.

Main Features of the CPWS
Self-Contained System, Small Footprint
The small footprint permits installation into existing or new lab spaces using conventional utilities and minimal site preparation. The CPWS individual docking incubators reduce product mix-up and cross-contamination errors. An optional built-in centrifuge and cell observation microscope/monitor further reduce laboratory space requirements as well as improve aseptic processing.

Higher Efficiency
By using a highly effective H2 O2 decontamination process, the CPWS can be completely sterilized without heat and prepared for the next protocol within two hours instead of the conventional cleanroom decontamination protocol that can take days or weeks.

Contamination-free Design
The four-port glove box delivers more than a conventional Class II, Type A2 biological safety cabinet typically installed within a cleanroom to achieve the same level of contamination or cross-contamination prevention. Centrifuge and incubator access from within the Class 100 work station environment enhances aseptic processing.

Other Key Features

  • Approximately 35% less expensive to operate than a conventional cleanroom (open system).
  • The barrier isolator creates a grade A or class 100 environment within the workstation (When installed in a class 100,000 cleanroom).
  • Gowning is not required, allowing for a significant improvement in user comfort and productivity upon entrance and exit from the aseptic environment.

About SANYO
SANYO Electric Co., Ltd. is a global, leading provider of energy, environment, and lifestyle applications. Biomedical Solutions, a Division of SANYO North America Corporation (a subsidiary of SANYO Electric Co., Ltd.), is based in Wood Dale, IL, and provides laboratory equipment for pharmaceutical, life science and biotechnology applications. Product lines include space-efficient VIP® ultra-low temperature freezers, cryogenic freezers, pharmaceutical and medical refrigerators, cell culture incubators, plant growth chambers, and portable autoclaves.
To learn more about SANYO, please visit http://us.sanyo.com

For Press Inquiries:
Aaron Fowles
SANYO North America Corporation
Office: 619-661-4151
Email: [email protected]

id=”nav_links”>

Filed Under: Hospitals and Health Systems

The Patient Channel and dLife Partner to Increase Diabetes Education in U.S. Hospitals

Posted on October 20, 2010 Written by Editor

SOURCE: Interactivation Health Networks

WESTPORT, CT–(Marketwire – October 20, 2010) –  The Patient Channel, the largest U.S. hospital-based health and wellness TV channel, and dLife, the only multi-media network serving the diabetes community, have announced a strategic partnership that will significantly increase year-round diabetes education, wellness, and lifestyle programming for patients and caregivers in over 1,600 hospitals across the U.S. The partnership will help diabetes educators and patients by providing vital information at a critical time of need increase awareness and self-management, help decrease future hospital visits and encourage ongoing engagement at home.

As part of the agreement, 14 hours of dLifeTV‘s diabetes lifestyle programming will be added to The Patient Channel’s existing diabetes line-up. The partnership will begin in the fourth quarter of 2010 and advertisers will be offered special tie-in opportunities to commemorate American Diabetes Month in November. The Patient Channel’s existing topics of diabetes prevention, treatments, and avoiding complications will be supplemented with dLifeTV episodes profiling real people overcoming the challenges of living with diabetes, as well as interviews with celebrities living with diabetes such as The View co-host, Sherri Shepherd, and CBS newsman, Bob Schieffer. There will also be special programming on topics as varied as religion and diabetes, diabetes in the workplace, and the latest diabetes gadgets.

Patients will be encouraged to watch dLifeTV (Sundays at 7 p.m. ET, 4 p.m. PT on CNBC), as well as join dLife’s award-winning website, dLife.com, which has over one million visitors each month.

“Diabetes diagnosis often happens in the hospital, and inpatient stays are often caused by diabetes and its complications. For many of them it can be a time of profound fear, confusion and isolation. Not to mention a supreme teachable moment to improve their diabetes IQ going forward. We are delighted by our new partnership with The Patient Channel, which allows us to put dLifeTV in front of people with diabetes at such a critical time of need,” says Howard Steinberg, CEO and founder of dLife.

“The Patient Channel hospital footprint reaches 35 percent of hospitalized Americans with or at risk for diabetes,” says Dave Ross, COO of The Patient Channel. “This programming will help hospitals and diabetes educators to educate and improve the compliance of patients and families at the very time they are motivated and seeking information to manage their condition and lifestyle.” 

For a full list of the diabetes programming running on The Patient Channel, as well as other details about The Patient Channel’s educational offering and platform, visit www.thepatientchannel.com.

For additional resources on managing your or your patients’ diabetes lifestyle, please go to www.dLife.com.

About Interactivation Health Networks
The Patient Channel and the Newborn Channel are the most comprehensive in-hospital TV networks. Delivered directly to patient rooms and waiting areas, the Channels provide viewers with original, award-winning health programs and advertisers with the unique ability to integrate brand messaging with content that is compelling and endorsed by healthcare professionals. The Newborn Channel broadcasts baby care and postpartum programming for new parents, reaching 60% of new moms. The Patient Channel features both condition-specific and preventative health programming to empower and inform patients. The channels are currently available in over 2,700 hospitals nationwide. For more information, visit www.thenewbornchannel.com and www.thepatientchannel.com

About dLife – For Your Diabetes Life
dLife is the only multimedia network serving the diabetes community. Its award-winning media outlets include dLife.com, the leading online destination for diabetes information, inspiration, and connection, featuring more than 9,000 recipes, 400 videos, and 80,000 pages of content; dLifeTV, the only lifestyle TV series for people with diabetes, airing every Sunday on CNBC (7 p.m. ET, 4 p.m. PT); and other consumer and professional programs to inform, inspire and connect people with diabetes and those who care for them every day.

Filed Under: Hospitals and Health Systems, Public Health and Research

Healthcare Providers Can Get Paid More Often, More Quickly Using New Sage Patient Payments Product

Posted on October 20, 2010 Written by Editor

SOURCE: Sage North America

Secure Payments Product Addresses, Authorizes, and Collects Patient Fees at Point of Care

MCLEAN, VA–(Marketwire – October 20, 2010) – Patient payments are an increasing and critical part of the overall revenue stream for today’s healthcare providers. With approximately 50% of patient payments being written off as bad debt; point-of-care payments solutions help ensure payment is both received and approved. Sage Payment Solutions, the payments division for Sage North America, today announced the launch of Sage Patient Payments, a secure payment solution that enables collections from patients at the point of care, regardless of the patient’s third-party payer.

“With co-pays, deductibles, and the balance not covered by the patient’s insurance provider, healthcare payments have been historically challenging for patients to figure out,” said Greg Hammermaster, president of Sage Payment Solutions. “This confusion results in doctors’ offices focusing more on billing, payment, and collections, which drives up their costs. Sage Patient Payments streamlines the payment process facilitating accurate and timely payment to the doctors’ office while mitigating the patients’ confusion.”

By the end of this year, about 35% of a provider’s total revenue will derive directly from patient payments, according to the McKinsey & Co. report, “Overhauling the US Health Care Payment System.” Sage Patient Payments provides everything needed to handle patient payments at the point of care. The product’s calculator instantly determines the estimated service charges for a patient, taking into consideration relevant health plan discount arrangements.

Powered by mPay Gateway, a leading developer of Payment Card Industry (PCI) certified financial technology products and services for the healthcare industry, Sage Patient Payments provides patients with a simpler, easier-to-understand billing process. Physicians can dramatically reduce their receivables, bad debt, and patient statement costs in three easy steps.

After reviewing a summary of charges with a patient, healthcare providers can swipe the patient’s credit or debit card and obtain the patient’s commitment to pay up to that amount. These steps allow healthcare providers to directly collect the exact amount owed at a later date, after the patient’s insurance company or other third-party payer determines what the patient owes. The patient is never charged more than the estimate, and the provider never needs to send another bill.

Other features of Sage Patient Payments tailored to the unique healthcare environment include: payment plans, health benefit plan eligibility lookup, and a check and cash log to track all patient payments.

In addition to Sage Patient Payments, Sage offers numerous products and services used by the healthcare industry, including Sage Intergy for practice management, Sage Intergy EHR for electronic health records, and Sage Transaction Services for electronic data interchange (EDI). Approximately 80,000 physicians and thousands of ambulatory care practices throughout North America use Sage software and services to better manage their practices and improve profitability.

For more information on Sage Patient Payments or other products and services from Sage Payment Solutions, please visit www.sagepayments.com or call 800-261-0240.

About Sage Payment Solutions
Sage Payment Solutions, the payments division for Sage North America, has been providing businesses and organizations with electronic payment systems for more than 20 years. The company makes electronic payment processing easy for more than 155,000 merchants, allowing them to accept multiple forms of payment, including credit and debit cards, electronic checks, Check21, gift and loyalty cards, and automatic recurring payment. Sage Payment Solutions provides a wide range of secure standalone and integrated payment processing solutions. Sage Exchange, its PA-DSS certified payments platform, integrates with many Sage software products to maximize the value of customers’ business systems with automatically updated credit and debit card transaction information. Future Sage Exchange releases will offer additional integrated payment capabilities, including advanced point-of-sale (POS) device integration, payment origination solutions, and cash management applications. For more information about Sage Payment Solutions, please call 800-261-0240, or visit www.sagepayments.com.

About Sage North America
Sage North America is part of The Sage Group plc, a leading global supplier of business management software and services. Sage North America employs 4,000 people and supports 3.1 million small and midsized business customers. The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs 13,100 people and supports 6.2 million customers worldwide. For more information, please visit the website at www.sagenorthamerica.com.

Press Contacts:
Cynthia Sutton
Sage North America
(703) 793-2700 x 3032
[email protected]

Filed Under: Hospitals and Health Systems

HCPlexus and Healthline Networks Partner to Enhance Patient-Physician Dialog With Point-of-Care Health Information

Posted on October 20, 2010 Written by Editor

SOURCE: HCPlexus

Agreement Provides Marketers With New Consumer and Physician Advertising Opportunities

PHILADELPHIA, PA–(Marketwire – October 20, 2010) –  At Digital Pharma East, HCPlexus, publishers of The Little Blue Book™ (TLBB), a trusted resource for 300,000 doctors, announced a partnership with Healthline Networks, a leading provider of intelligent health information services reaching more than 100 million consumers each month, to provide pharmaceutical companies with a solution to inform physicians and patients on modes of treatment and care choices. As part of the strategic relationship, the companies will extend their current advertising networks, as well as the new point-of-care information platform, to provide contextual and direct marketing program offerings to Direct to Physician (DTP) and Direct to Consumer (DTC) pharmaceutical marketers.

The joint offering will support and deliver physician-mediated patient education at the point of care. Through the alliance, physicians will continue to receive high-quality, medically credible content delivered from a reliable resource, The Little Blue Book, augmented with patient education resources from Healthline. Sponsorship opportunities will be made available to pharmaceutical manufacturers, allowing them to benefit from increased consumer engagement and brand presence.

“As consumers embrace the HealthWeb, physicians need to play a central role in providing their patients with the highest quality, most contextually relevant health information,” said West Shell III, Chairman and CEO, Healthline Networks. “Our partnership with HCPlexus will enable physicians and patients to engage in shared decision-making around health care treatment options, thereby elevating health literacy and compliance.”

Adds HCPlexus CEO David L. Shrier, “Our pharmaceutical and payor clients have been demanding one stop shopping for marketing solutions aimed at both HCP and consumer audiences. Healthline is an innovative partner with scope and depth in the online consumer health market and the largest condition-specific DTC advertising network. We look forward to offering pharmaceutical companies more opportunities to help physicians and consumers make informed healthcare decisions.”

In a survey conducted by HCPlexus last December of more than five hundred physicians, 42% said they were looking for patient education from The Little Blue Book.

About HCPlexus
HCPlexus provides physicians with personalized, timesaving and multi-platform products so they can focus on healing patients. At the heart of the company’s physician-focused offerings is The Little Blue Book (TLBB), a referral directory, which for more than 20 years has been a trusted and high usage resource for healthcare providers. The Little Blue Book data is now available on-line and in a mobile phone application. Leveraging the deep insights gleaned from more than 400,000 TLBB physicians, HCPlexus delivers high ROI marketing programs to pharmaceutical companies, medical device manufacturers, pharmacies, hospitals, health plans and independent practice associations. For more information, visit http://www.hcplexus.com.

About Healthline
Healthline Networks is a leading provider of intelligent health information services, enabling 100 million consumers a month to make more confident, informed healthcare decisions. The company’s proprietary consumer healthcare taxonomy, the largest of its kind, powers a suite of intelligent health search, content and advertising services. Combining advanced search technology with deep medical expertise, Healthline partners with a network of over 40 trusted destination sites that include publishers, portals, search engines, employers and health plans. Headquartered in San Francisco, Healthline is backed by Aetna, GE/NBC Peacock Fund, Investor Growth Capital, Kaiser Permanente, Reed Elsevier, U.S. News & World Report, and VantagePoint Venture Partners. For more information, visit http://www.healthline.com.

Media Contacts:
Darlene Hollywood
Darlene Hollywood Public Relations, for HCPlexus
781/837-2572 (O)
781/264-0511 (M)
Email Contact

Jennifer Conway
Dotted Line Communications, for Healthline Networks
978-463-0289
Email Contact

Filed Under: Hospitals and Health Systems, Prescription Drugs and Pharmacy

New National Health Organization Forms: AAOSH

Posted on October 20, 2010 Written by Editor

SOURCE: American Academy for Oral Systemic Health (AAOSH)

American Academy for Oral Systemic Health Seeks to Connect Oral and General Health for Public, Physicians

MADISON, WI–(Marketwire – October 20, 2010) –  A group of health care leaders from across the country convened at Madison’s Monona Terrace Community and Convention Center on October 16, 2010 to hold the founding meeting for the American Academy for Oral Systemic Health (AAOSH, www.aaosh.com). The new organization has 50 founding members and anticipates rapid growth as more and more professionals absorb the data that demonstrates the close relationship of mouth health to body health and vice versa.

“When dentists and physicians work together, medical outcomes will be improved and lives will be lengthened,” states AAOSH President Dr. Chris Kammer, the nation’s most active advocate for an oral systemic approach to disease prevention. “Many people still don’t understand that good dental health can add years to your life, so one of our missions is to educate the public about the facts.”

The newly-inaugurated AAOSH will bring together medical professionals from all fields and try to eliminate the “tunnel vision” that can exist between medical specialties. Members will commit themselves to working and learning together in the ultimate spirit of cooperation so that patients everywhere can enjoy the resulting benefits of improved general health, healing, longevity and wellness.

“We’re excited about finally working closely with cardiologists, diabetic specialists, obstetricians and many more medical specialties,” explains Kammer. “AAOSH is all about opening those doors of communication and offering to help, so that we can contribute to the improved health for the patients we share.”

Several nationally-known clinicians who attended the meeting gave presentations on the latest findings related to the seriousness of oral disease in America. One speaker revealed how a couple was not able to conceive a child until the mother’s rampant gum infection was put under control. Another speaker discussed how diabetes can make gum disease worsen, but that gum disease can also make diabetes worse — a vicious “circle of death” unless dentists and physicians unite and intervene.

In addition, advanced dental techniques and systems for treating periodontal disease and tooth decay were shared, as well as an extended program on the importance of nutrition.

“The formation of this organization could not have come at a better time,” adds Kammer. “More and more research just keeps pouring in that confirms the connections between the health of the mouth and the resulting health of the body.”

Media Contact:
Dr. Chris Kammer
608-347-4045
Email Contact

Click here to see all recent news from this company

Filed Under: Hospitals and Health Systems

Simulated Environment Concepts Continues to Garner Significant Interest, Exposure and Sales Within Medical Community

Posted on October 20, 2010 Written by Editor

SOURCE: Simulated Environment Concepts

International Tradeshow Dedicated to Physiotherapists Attracts New Sales and Interest in SpaCapsule

MIAMI, FL–(Marketwire – October 20, 2010) –  Simulated Environment Concepts (PINKSHEETS: SMEV), the manufacturer and developer of medical, aesthetic and wellness equipment, increases its global medical appeal with a successful tradeshow hosted by Salon Rééducca — a show dedicated to Physical Therapy and Rehabilitation Practices. There, more than 200 physiotherapists tested the company’s flagship product, SpaCapsule, receiving increased interest and sales as a result.

Dr. Ella Frenkel, Chairman and CEO of Simulated Environment Concepts (SE Concepts), Inc. said, “With all of the excitement swirling around our corporate orders, installations in hotels and fitness centers as well as the major distribution contracts, it could be forgotten that the Spa Capsule is a medical grade product. So while our capsules can certainly be used for relaxation, as medical equipment, the Spa Capsule’s foremost purpose is to assist physical therapists and doctors in delivering therapeutic treatments to patients.” 

Zen & O, a French distribution company with which SE Concepts has a multi-million dollar four year manufacturing deal, supported SE Concepts by displaying the H2O Body System – SpaCapsule at Salon Rééducca’s tradeshow last week. Roughly 225 physiotherapists tested the Spa Capsule units giving higher than expected approval ratings — with Zen & O capturing significant interest of nearly two dozen physical therapists resulting in multiple units sold at the show. 

Sales within the global medical community expected to continue as medical equipment providers and PT (Physical Therapy) centers look to distribute and own the Spa Capsule. SE Concepts has plans for an upcoming November tradeshow where the company anticipates further growing its international distribution base and medical appeal worldwide.

About Simulated Environment Concepts, Inc.

Simulated Environment Concepts, Inc. (SE Concepts) is an industry leading manufacturer and developer of cutting edge medical, health and wellness equipment.    

Its flagship product, SpaCapsule®, is a high pressurized dry water massage therapy system used for rehabilitation, relaxation, weight loss, cellulite management and general wellness.  Using its patented dual “dry-barrier” environment, users can remain fully clothed — a matter of gender and cultural significance within the markets the SpaCapsule is offered.  The product can be found in over 37 countries, offered by medical clinics, gyms and fitness centers, spas, retail locations, corporate offices, luxury hotels, and other venues.  Incorporating self contained oxygen, aromatherapy and iPod compatible audio/video features, users receive an enjoyable, rehabilitating and de-stressing therapeutic experience. 

The SpaCapsule has been featured on numerous Network and cable television programming including Good Morning America and The Doctors, and continues to receive global publicity.

For more information on SE Concepts, SpaCapsule®, PTjetCapsule™ and Celude Laboratories™ products you can visit the company’s product website at www.spacapsule.com, the corporate website at www.seccorporation.com, the corporate blog at http://www.spacapsule.wordpress.com or request more information via email at [email protected], or call at (888) 757-0797 or (305) 651-9200.

Safe Harbor

Statements in this news release that are not historical facts, including statements about plans and expectations regarding products and opportunities, demand and acceptance of new or existing products, capital resources and future financial results are forward-looking. Forward-looking statements involve risks and uncertainties which may cause the Company’s actual results in future periods to differ materially from those expressed. These uncertainties and risks include changing consumer preferences, lack of success of new products, loss of the Company’s customers, competition and other factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

SpaCapsule is registered trademark of Simulated Environment Concepts, Inc.

For further information, contact:
At The Company:
Simulated Environment Concepts
Investor Relations Department
(888) 757-0797

Click here to see all recent news from this company

Filed Under: Hospitals and Health Systems

Allied Healthcare International Inc. to Present at the Oppenheimer 21st Annual Healthcare Conference

Posted on October 20, 2010 Written by Editor

SOURCE: Allied Healthcare International Inc.

NEW YORK, NY–(Marketwire – October 20, 2010) –  Allied Healthcare International Inc. (NASDAQ: AHCI), a leading provider of flexible healthcare staffing services in the United Kingdom, announced today that Sandy Young, the Company’s Chief Executive Officer, will be presenting at the Oppenheimer 21st Annual Healthcare Conference to be held on November 2-3, 2010 at the Waldorf=Astoria in New York City.

Allied’s presentation is scheduled for Wednesday, November 3, at 4:30 p.m. Eastern Time.

The presentation will be webcast live and will be available on the Investors section of Allied’s website at www.alliedhealthcare.com. For those who are not available to listen to the live broadcast, the presentation will be archived.

About Allied Healthcare International Inc.
Allied Healthcare International Inc. is a leading provider of flexible healthcare staffing services in the United Kingdom. Allied operates a community-based network of approximately 115 branches with the capacity to provide carers (known as home health aides in the U.S.), nurses, and specialized medical personnel to locations covering approximately 90% of the U.K. population. Allied meets the needs of private patients, community care, nursing and care homes, and hospitals. For more news and information please visit: www.alliedhealthcare.com.

CONTACT

Allied Healthcare International Inc.
Sandy Young
Chief Executive Officer
Paul Weston
Chief Financial Officer
+44 (0) 17 8581 0600

Or

ICR, LLC
Sherry Bertner
Managing Director
+1 646 277 1200
[email protected]

Filed Under: Hospitals and Health Systems

This Week on ORLive: Surgical Approaches — Adhesion Prevention and Chronic Low Back Pain

Posted on October 19, 2010 Written by Editor

SOURCE: BroadcastMed, Inc.

New On-Demand and Live Medical Video From BroadcastMed for the Week of October 18, 2010

WEST HARTFORD, CT–(Marketwire – October 19, 2010) –  BroadcastMed, the leader in online medical video, starts the week with a live broadcast intended for European audiences focused on Adhesion Prevention in Gynaecological Surgery. Later in the week the focus turns to low back pain in a live broadcast of a minimally invasive spine surgery. Rounding out new content this week are new on-demand CME features available on our BroadcastMedCME channel.

Additional on-demand features this month include our library of procedures and educational programming focused on breast cancer surgeries and BroadcastMed invites you to take part in the latest installment of the Virtual Brain Tumor Board.

NEW ON ORLIVE

LIVE SURGERY VIDEO – Contemporary Adhesion Prevention In Gynaecological Surgery

Premieres Tuesday, October 19, 2010 at 2:30PM EDT/19:30 GMT

Participate in this live interactive webcast as gynaecological surgeons Prof. Jeremy Wright and Mr. Andrew Kent review surgical footage and discuss the inherent challenges with conventional adhesion prevention techniques. The faculty will share case reports and will contrast the pros and cons of available options, including the SprayShield™ adhesion barrier system.

This program features the SprayShield™ adhesion barrier system. It is intended for audiences outside the United States where the SprayShield™ system has CE Mark approval, and is indicated for use in patients undergoing laparotomy or laparoscopic abdominopelvic surgery as an adjunct to good surgical technique intended to reduce the incidence, severity, and extent of postsurgical adhesions.

This surgery video is available exclusively to members of the ORLive community, and members can interact and ask questions via the ORLive website. Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

LIVE SUGERY VIDEO – Treating Chronic Back Pain with Minimally Invasive Surgery

Premieres Thursday, October 21, 2010 at 4PM EDT

Surgery for chronic back pain doesn’t have to mean a long stay in the hospital and a slow recovery. On Thursday, October 21, Baptist Hospital neurosurgeon Sergio Gonzalez-Arias, MD, will perform a minimally invasive spine surgery during a live webcast. The minimally invasive approach is used to relieve various types of pain. The advantages over a traditional surgical procedure are less blood loss, less pain, smaller incisions and a quicker recovery. Many patients go home the same day of the surgery. Watch the live webcast and see this fascinating procedure as it happens. 

Viewers are invited to send e-mail questions to Dr. Gonzalez-Arias during the webcast.

Viewers can also choose to watch the webcast in Spanish.

Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NEW CME ON BROADCASTMED

NEW CME VIDEO — Antiplatelet Therapy: Difficult Situations in Everyday Practice

Premiers Tuesday, October 19, 2010

Join Doctors from multiple specialties discuss common solutions for the management of patients requiring antiplatelet therapy. Presenters include cardiologist Oscar C. Marroquin, MD, internists Robert E. Schoen, MD MPH and Catalin Toma, MD, and surgical oncologist A. James Moser, MD, FACS.

Educational Objectives

  • Draw informed clinical decisions in cardiovascular medicine.
  • Cite responsible and balanced debate on conventional and controversial issues in the area of cardiovascular medicine.
  • Discuss the management of patients with asymptomatic aortic stenosis.
  • Forecast and discuss important issues and trends in cardiovascular medicine.

You can find more CME on the BroadcastMed CME Channel on ORLive.com, and a complete multispecialty library of CME offerings at the UPMC Physician Resources website.

ORLIVE REFERRALS — Week of October 18, 2010
October is National Breast Cancer Awareness Month, and each week ORLive highlights related on-demand videos for our membership and visitors. 

Breast Cancer Surgery Referral: Surgical Advances in Axillary and Sentinel Lymph Node Dissection, from Ethicon Endo-Surgery

CME Referral: New Perspectives in Sepsis for the Critical Care Nurse, from CMEducation Resources

Viewer’s Referral: Cancer and Thrombosis Management: DVT and Prophylaxis and Disease Modification in Cancer Patients, from CMEducation Resources

HIGHLIGHTS

NOW ON-DEMAND – LEGION™ Total Knee System with VISIONAIRE™ Patient Matched Insturmentation

Now Available On-Demand

Kenneth Cherry, MD will demonstrate his approach to address efficiency in the OR by utilizing the LEGION Total Knee System in conjunction with VISIONAIRE Patient Matched Instrumentation while Dr. Steven Haas, from the Hospital for Special Surgery in New York City, moderates the procedure. Combining the two technologies, will reduce OR time and eliminate up to 23 surgical steps from the TKA procedure thereby making efficiency more accessible.

Learn more about this broadcast or get a reminder at ORLive.com, and be ready to view this exciting procedure by activating your free membership to ORLive today.

NOW ON-DEMAND — Acute Onocologic Emergencies

Now Available ON-Demand

Join Ahmad Tarhini, MD as he reviews onocologic emergencies in this presentation from a recent UPMC Medical Grand Rounds.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Better manage epidural spinal cord compression in patients.
  • Better management of hypercalcemia of malignancy in cancer patients.
  • Increase the management of superior vena cava syndrome in cancer patients.

You can find more CME on the BroadcastMed CME Channel on ORLive.com, and a complete multispecialty library of CME offerings at the UPMC Physician Resources website.

About BroadcastMed
BroadcastMed is the leading provider of video communication channels and solutions to the healthcare community. Working collaboratively with hospitals, device manufacturers, and pharmaceutical companies, BroadcastMed produces and distributes customized, interactive, video programs that demonstrate the latest advances in medicine, surgical techniques and product innovations, and promotes them to a verified audience of more than 700,000 healthcare professionals. The BroadcastMed network of sites provides an intimate look at over 650 live and on-demand surgeries, medical education, and symposia to global audiences that watch and learn from more than 40 million video views annually. The BroadcastMed network can be found on-line at www.BroadcastMed.com. 

Contact:
Bonnie Gergely
Communications Manager
(860) 953-2900
Email Contact

id=”nav_links”>

Filed Under: Hospitals and Health Systems

Percée sur le marché américain : La solution québécoise Extenway en service dans une clinique externe du Memorial Sloan-Kettering Cancer Center…

Posted on October 19, 2010 Written by Editor

MONTRÉAL, QUÉBEC–(Marketwire – 19 oct. 2010) –

Note aux éditeurs : Une photo accompagnera ce communiqué de presse sur le site de Marketwire.

Quelques semaines à peine après la mise en service de sa solution à l’Hôpital juif de réadaptation de Laval au Québec, Solutions Extenway inc. (TSX CROISSANCE:EY) est heureuse d’annoncer que c’est maintenant au tour des patients du centre de traitement de chimiothérapie du Memorial Sloan-Kettering Cancer Center situé à Brooklyn, à New York, de profiter des avantages offerts par ses terminaux. Cette annonce marque la première phase du déploiement de la solution technologique Extenway en sol américain.

Une solution pour améliorer la qualité de vie des patients en milieu hospitalier

Les terminaux de chevet Extenway permettent aux patients de profiter à la fois d’un moyen de communication avec le personnel et leurs proches (vidéoconférence et service d’assistance), d’une plateforme de divertissement numérique (télé, jeux, lecteur MP3, radio et livres audio) et éducatif (capsules d’enseignement aux patients), ainsi que d’un environnement de bureautique (Internet, courriel, Microsoft Office, etc.).

« Notre solution permet aux patients de vivre une expérience plus positive durant leur traitement, a déclaré John McAllister, président et chef de la direction d’Extenway, une entreprise de Baie d’Urfé, dans la région de Montréal. Certains d’entre eux passent parfois de longues semaines en milieu hospitalier et les témoignages que nous avons reçus confirment que notre technologie améliore leur qualité de vie durant cette période. »

Les patients peuvent consulter les contenus proposés en utilisant l’écran tactile ou le clavier sans fil des terminaux. Dans le cas du Memorial Sloan-Kettering Cancer Center, il était très important d’offrir un environnement agréable et le moins « hospitalier » possible à ses patients. Le panneau d’installation mural des terminaux Extenway a été adapté afin que ces derniers puissent être fixés directement sur les chaises de traitement de chimiothérapie.

Une solution pour améliorer l’efficacité des services hospitaliers

La solution Extenway permet aussi de maximiser la communication entre le patient, les cliniciens et le personnel.

Les patients peuvent notamment consulter les menus et transmettre leurs sélections en ligne, ou encore contrôler la lumière et la température de leur chambre sans se déplacer. En étant plus autonomes, les patients permettent ainsi au personnel de se concentrer davantage sur les besoins médicaux.

Extenway tiendra sa prochaine assemblée annuelle et spéciale de ses actionnaires le 21 octobre à 11 h, au salon Musset du Centre Sheraton Montréal situé au 1201, boulevard René-Lévesque Ouest.

À propos de Solutions Extenway inc.

Solutions Extenway (TSX CROISSANCE:EY) (www.extenway.com) est un fournisseur de solutions technologiques d’information, de communication, de divertissement et d’éducation dans le domaine de la santé. Les terminaux Extenway offrent une vaste gamme de contenus et services intégrés dont la télévision, Internet, Microsoft Office, la vidéoconférence, la gestion de l’environnement des chambres des patients et la gestion des rendez-vous des patients. Basée à Baie d’Urfé, dans la région de Montréal au Canada, Extenway permet aux organisations d’optimiser la gestion et la coordination des interactions entre les partients et le personnel médical et administratif.

Clause libératoire et d’exonération

À l’exception des informations concernant les antécédents de l’entreprise ci-haut mentionnées, ce communiqué contient des déclarations futures qui impliquent des risques et des incertitudes. Les résultats réels peuvent être différents au niveau matériel. Les facteurs qui peuvent causer une différence incluent, mais ne sont pas limités à, l’acceptation des produits au niveau du marché, l’impact des produits compétitifs et technologies, la possibilité que certains produits portent atteinte aux brevets et autres propriétés intellectuelles de tierces parties, et aux coûts associés aux développements de produits. Solutions Extenway inc. ne procédera pas à la mise à jour de ces déclarations futures afin de refléter les événements ou circonstances après la date ci-haut mentionnée. Des informations plus détaillées sur les facteurs potentiels qui pourraient avoir une influence sur les résultats financiers sont incluses dans les documents fournies aux autorités canadiennes en valeurs mobilières.

Filed Under: Hospitals and Health Systems, Public Health and Research

Breakthrough on the American Market: The Canadian Solution Extenway Is Put Into Service at an Outpatient Facility of Memorial Sloan-Kettering Cancer…

Posted on October 19, 2010 Written by Editor

MONTREAL, QUEBEC–(Marketwire – Oct. 19, 2010) –

Editors note: A photo will be included with this press release on Marketwire’s website.

Just weeks after its solution was put into service at the Jewish Rehabilitation Hospital of Laval in Quebec, Extenway Solutions Inc. (TSX VENTURE:EY) is delighted to announce that its terminals will now be used by patients at an outpatient chemotherapy center of Memorial Sloan-Kettering Cancer Center in Brooklyn, New York. This announcement marks the first time Extenway’s technology solution has been deployed on American soil.

Improving the quality of life for hospital patients

Extenway’s bedside terminals allow patients to benefit from a means of communication with staff and family (via video conference and assistance request service), a digital entertainment platform (TV, games, MP3 player, radio, and audio books), educational tools (patient teaching capsules), and a desktop work environment (Internet, email, Microsoft Office, etc.).

“Our solution allows patients to have a more positive experience during their cancer treatment“, said John McAllister, President and CEO of Extenway, a company based in Baie d’Urfé in the Montreal region. “Patients sometimes have to spend weeks at a time in hospital, and feedback confirms that our technology improves their quality of life during this period.”

Patients can consult the different contents by using the terminal’s tactile screen or a wireless keyboard. For Memorial Sloan-Kettering Cancer Center, it was very important to provide a positive and not “hospital-like” environment for patients. Extenway typical wall installation was adapted for direct mounting of the terminal onto the chairs used for chemotherapy treatment, thus creating a better patient experience.

Improving the efficiency of hospital services

The Extenway solution also helps optimize communication between the patient, clinicians and hospital staff.

Patients can also consult online menu and send their orders online. They can even adjust the light and temperature in their room – without having to move. Patients are therefore more autonomous, allowing staff extra time to concentrate on their medical needs.

Extenway will hold its next general meeting for shareholders on October 21 at 11am in the Musset room of Le Centre Sheraton Montreal, located at 1201 boulevard René-Lévesque West.

About Extenway Solution Inc.

Extenway Solutions (TSX VENTURE:EY) (www.extenway.com) provides IT, communications, entertainment and education solutions to the healthcare sector. Extenway terminals offer a wide range of integrated content and services, including television, Internet, Microsoft Office, and video conferencing. The terminals also offer the possibility of managing patient appointments and regulating a patient’s bedroom environment. Extenway allows healthcare organizations to optimize the way they manage and coordinate interactions between patients, medical staff and those working in administration. The company is based in Baie d’Urfé in the Montreal region of Canada.

Disclaimer – Safe Harbour Forward–Looking Statements

Certain statements contained in this press release constitute forward-looking statements. These forward-looking statements relate to the future financial conditions, results of operations or business of the Company. These statements may be current expectations and estimates about the markets in which Extenway Solutions Inc. operates and management’s beliefs and assumptions regarding these markets. These statements are subject to important risks and uncertainties which are difficult to predict and assumptions which may prove to be inaccurate. The results or events predicted in forward-looking statements may differ materially from actual results or events. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. In particular, forward-looking statements do not reflect the potential impact of any merger, acquisitions or other business combinations or divestitures that may be announced or completed after such statements are made.

Filed Under: Hospitals and Health Systems

Doctors Deliver Historic 50,000th Baby at Holy Family Hospital of Bethlehem

Posted on October 19, 2010 Written by Editor

SOURCE: Holy Family Hospital

Milestone Birth at West Bank Hospital Seen as Symbol of Peace for Holy Land

WASHINGTON, DC–(Marketwire – October 19, 2010) –  She is a ray of hope, arriving Oct. 18 in one of the world’s poorest, most volatile regions. She is Aisha — the 50,000th baby born at Holy Family Hospital of Bethlehem.

“This is a very special moment for the hospital, for us, for our future and especially for the mother,” said Dr. Jadallah Najjar, who delivered the baby and is head of Holy Family Hospital’s Gynecology and Obstetrics Department. “I hope there will be peace in this land, and that this birth is a symbol of that peace.”

At 9:30 a.m. local time on Oct. 18, 2010, Dr. Najjar delivered Aisha to Hafsah Omar Radaydiah, 19, and her husband Isam, 24. She weighed 7.5 pounds and was 19.7 inches long. Mother and baby are doing well!

 “I am so happy,” Hafsah Radaydiah said. “I have been waiting to become a mother. This will change my whole life. I’m happy because she is so beautiful.”

“We’ve just heard the exciting news,” said Colleen Marotta, executive director of the Washington, D.C.-based Holy Family Hospital Foundation. “We are thrilled to welcome the 50,000th life at our hospital.”

“This birth is very exciting and symbolic,” said Dr. Jacques M. Keutgen, general director of the hospital. “A young lady, 19 years old, giving birth to her first baby. This is the future of this hospital.”

The Sovereign Military Order of Malta has operated Holy Family Hospital of Bethlehem since 1990 at the request of Pope John Paul II who declared the Hospital one of the top 100 global priorities for the new millennium. Over the past 20 years, it has provided a variety of maternity, gynecological and pediatric services to families in the region without regard to race, religion or ability to pay. Located only 500 yards from the traditionally recognized birthplace of Jesus, no family has ever arrived at its doors to hear that “there is no room.”

In addition to Colleen Marotta of the U.S.-based Foundation, hospital staff are available for limited interviews. Please contact Christine Schicker of The Maximus Group at 404-610-8871 or by email at [email protected]. To learn more about the hospital, or download press materials and photos, please visit www.BirthplaceofHope.org.

FOR INFORMATION CONTACT:
Christine Schicker
404-610-8871
Email Contact

Filed Under: Hospitals and Health Systems

MEDIA ALERT: GetWellNetwork Featured Speaker for American Hospital Association Webinar on the Financial Impact of New Health Care Provisions

Posted on October 19, 2010 Written by Editor

SOURCE: GetWellNetwork

Pay for Performance and Value-Based Purchasing Provisions Likely to Impact CMS Reimbursements

BETHESDA, MD–(Marketwire – October 19, 2010) –  GetWellNetwork, Inc. today announced that the company’s Chief Outcomes Officer, David Wright, and Chad Mulvany, Healthcare Financial Management Association, will share how new health care provisions such as Value-Based Purchasing(1) will impact U.S. hospitals’ reimbursements by CMS. 

Mr. Wright and Mr. Mulvany will provide attendees with a thorough overview of the new health care law and “Pay for Performance” provisions, as well as to demonstrate how interactive patient care technologies are raising performance measurements used by CMS to measure hospitals’ effectiveness in treating patients — in areas of quality, safety, cost and satisfaction. 

Attendees will also hear how leading hospitals and health systems are using interactive patient care solutions to achieve evidence-based outcomes and improve hospital performance in the areas that directly impact the “Pay for Performance” provisions.

Date: October 20, 2010
Time: 1:00-2:00 PM EST
To Register Click: Using Patient Engagement to Prepare for the Pay for Performance

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

(1) More information about CMS’ Value-Based Purchasing Program is available at http://www.cms.gov/AcuteInpatientPPS/downloads/HospitalVBPPlanRTCFINALSUBMITTED2007.pdf and http://www.cms.gov/QualityInitiativesGenInfo/downloads/VBPRoadmap_OEA_1-16_508.pdf

Media Contact:
Jenny Song
(703) 338-8434
Email Contact

Filed Under: Hospitals and Health Systems, Medicare

Healthcare IT Solutions Exchange (HITSE) Announces Speakers and Session Updates for Upcoming HITSE New England Conference

Posted on October 19, 2010 Written by Editor

SOURCE: Interbit Data

Conference Benefiting Hospital Information Systems Users Takes Place October 26 and 27 in Westborough, MA

NATICK, MA–(Marketwire – October 19, 2010) –  The Healthcare IT Solutions Exchange (HITSE) announces its slate of speakers and updates on tracks to be featured at its healthcare IT conference, HITSE New England 2010, to be held October 26 and 27 at the Doubletree Hotel, Westborough, MA. This is the first in a series of conferences to provide healthcare IT professionals with continuing education, purchase planning assistance and peer networking around issues facing hospitals and healthcare systems. 

HITSE New England‘s speakers include healthcare industry experts and CIOs, who will discuss topics related to the four conference tracks:

  • Computerized Physician Order Entry (CPOE);
  • Meaningful Use;
  • Migrating to MEDITECH 6.0; and
  • Revenue Cycle Management. 

Each track includes two speaker presentations, one panel discussion and an interactive session with vendors responding to issues raised by the speakers and attendees. Issues such as interoperability, business continuance and workforce scheduling will be addressed and case studies, product demonstrations and participation in user group discussions will be offered.

Key presentations are scheduled featuring the following speakers:

  • Ray Campbell, Executive Director and CEO, Massachusetts Health Data Consortium, provides information and updates on Meaningful Use; 
  • Dr. Cupid Gascon, Medical Director of Emergency Services at Oswego Hospital, discusses CPOE: A Physician’s Perspective;
  • Bill O’Toole, Founder of O’Toole Law Group, provides valuable insight on Contract Considerations for MEDITECH 6.0;
  • Ron Kilmer, Patient Services Manager at Nathan Littauer Hospital, presents The Evolving Role of Case Management in the Revenue Cycle; and
  • Chuck Duncan, CEO of Healthcare Revenue Strategies, shares his experience in Effective Revenue Cycle Management.

“By organizing the HITSE New England conference, we are trying to leverage the benefit of peer-to-peer interaction, particularly to the delivery of healthcare,” states Arthur Young, president of Interbit Data and one of the founding HITSE members. “Healthcare IT professionals will have the opportunity to share experiences and exchange information and best practices, as well as collaborate with vendors on implementing solutions.”

All members of the healthcare IT community can participate and benefit from HITSE, including CIOs, IT managers, IT department managers, IT staff and consultants, as well as IT vendors. Vendor exhibition and sponsor opportunities have already sold out for this conference, however vendors are welcome to register as conference attendees.

More information on HITSE New England conference registration can be found at http://www.hitse.org.

About Interbit Data
Founded in 1997 and named to the 2009 and 2010 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Contact:
Beth Bryant
508-786-3013
Email Contact

Click here to see all recent news from this company

Filed Under: Healthcare Business, Hospitals and Health Systems

Bob Honigberg, MD Is Named Medical and Healthcare Strategy Director at Quantum Health

Posted on October 19, 2010 Written by Editor

SOURCE: Quantum Health, Inc.

COLUMBUS, OH–(Marketwire – October 19, 2010) –  Robert M. Honigberg, MD, MBA has joined the innovative Quantum Health as the company’s new consulting Medical and Healthcare Strategy Director.

Dr. Honigberg is also the current Chief Medical Officer of URAC (Utilization Review Accreditation Commission) in Washington, D.C., and is a steering committee member of the Aspen Health Stewardship Project and on the Board of Directors of the Center for International Health. 

As Quantum Health’s Medical and Healthcare Strategy Director, Dr. Honigberg will evaluate strategic opportunities and review Quantum Health’s programs to ensure patient safety and promotion of healthcare quality as well as provide guidance on reporting and publication of data. “As a physician focused on quality and innovative solutions, I am especially attracted to Quantum Health’s approach and creation of ‘Virtual Medical Homes’ to both improve quality and reduce waste and inefficiencies. I think it’s the right approach and their track record proves the efficacy,” said Dr. Honigberg.

“Healthcare is undergoing seismic change in the United States; adding Bob to our team strengthens our ability to grow with consistent and sustainable focus on quality. His unique background will also contribute to the already very positive relationships we have with providers across the country,” remarks Kara Trott, founder and CEO of Quantum Health. “His overall thought-leadership and influence will only strengthen our ability to continue to help make healthcare more effective for physicians and patients alike.”

Dr. Honigberg was recently the Chief Medical Officer, Global Medical Affairs and Clinical Strategy, for GE Healthcare’s $17 billion portfolio, which is a unit of the General Electric Company that provides a broad range of products and services to better diagnose and treat cancer, heart disease, neurological disease and other medical conditions earlier. Dr. Honigberg was responsible for strategies and operations related to clinical research and trials, the protection of patient safety, and medical communication to providers and governments. Before joining GE Healthcare, he was the Vice President, Worldwide Medical Affairs and Chief Medical Officer, at Ethicon Endo-Surgery, a Johnson & Johnson Operating Company, for seven years. He undertook his internship and residency in surgery at Montefiore Hospital and the Albert Einstein College of Medicine in New York City. His educational background includes a B.A. in Economics from Duke University, an MD from the Feinberg School of Medicine at Northwestern University, and an MBA from the Kellogg School of Management at Northwestern University. 

ABOUT QUANTUM HEALTH
Quantum Health is an award-winning and fundamentally different health care company headquartered in Columbus, Ohio, serving employers nationally.

Quantum Health guarantees their clients a 5-8% reduction in total claims spend. By reorganizing benefits delivery and creating a “virtual medical home” for each member, Quantum Health maximizes each service opportunity to intercept patients when they have a problem to solve or questions about their benefits or healthcare. Real time, informed involvement allows our Care Coordinators to help patients, their families, and their physicians to work together to ensure proper care, eliminating redundant, delayed and questionable care — literally driving unnecessary medical events and cost out of the system. All with a 100% guarantee.

Filed Under: Hospitals and Health Systems

First China Pharma Increases Market Share With Announcement of New Distribution Agreement at 3 Regional Hospitals in China

Posted on October 19, 2010 Written by Editor

SOURCE: First China Pharmaceutical Group, Inc.

HONG KONG–(Marketwire – October 19, 2010) –  First China Pharmaceutical Group, Inc. (OTCBB: FCPG) (“First China” or the “Company”) is pleased to announce it has recently signed agreements to distribute medicinal and pharmaceutical products to three district hospitals in Yunnan Province, thereby dramatically increasing its regional market share.

The agreement comes, in part, as a result of a proposal put forward in 2009 by the Ministry of Health during the National Health Conference that public hospitals should gradually phase out the existing 15% medicines and pharmaceutical products “cost plus” pricing system within 3 years. The government also advised that medical institutions should centralize their procurement and distribution of drug and pharmacare products.

These new guidelines identified that the previous system maintained high prices and commissions which have been deemed unsustainable and that these institutions should move towards agreements with large scale pharmaceutical distributors. This new methodology has been welcomed and is increasingly becoming popular as many leading hospitals and clinics move to this new system of procurement.

This news has been welcomed at First China and the results are just now coming to fruition with these new contracts now in place with the Yunnan No. 1 Peoples Hospital as well as the Kunming Yanan and Lin Cang Peoples Hospitals. The Company is perfectly positioned to take advantage of this Government approved purchasing directive and stands ready to be catapulted into the forefront of this rapidly growing market segment.

First China’s combination of bulk purchasing, low prices and growing variety of product lines (both Chinese and Western) complements its high capacity supply chain and B2B operating system all of which fully utilizes and exploits the benefits of their exclusive government issued internet ordering and distribution license. As a result, the Company is daily increasing its differentiation from the rest of the competition in this region of over 45 million inhabitants. 

Currently any hospital or clinic in Yunnan Province can easily sign up to procure the medicines they need from First China, enjoying instant response, rapid fulfillment and secure services combined with excellent price points, allowing those institutions to recover increased margins while offering lower retail pricing in many instances.

First China Pharmaceutical Group plans to continue the growth of the company from its current position as a provider of approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. The Company anticipates its business model will change to leverage the efficiencies of internet ordering and fulfillment and intends to rapidly expand its capacity to approximately 30,000 products. It is estimated that a broader product line will ensure customers will be able to order 80% to 90% of their product needs directly from the Company.

The Definitive Agreement contains customary representation and warranties, covenants and indemnification provisions and conditions. Details of the company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About First China Pharmaceutical Group, Inc. (OTCBB: FCPG)
First China Pharmaceutical Group, Inc. aims to develop a high growth pharmaceutical distribution company generating significant revenue from the sale of healthcare products in China. As part of its business strategy, the Company has acquired the assets of Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT), which includes a strategic advantage over its competitors as it is the only pharmaceutical distribution company in Yunnan Province that has obtained government approval to fulfill orders over the internet. First China Pharmaceutical Group plans to continue the rapid growth of the company from its current position as a provider of approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. For more information visit: www.firstchinapharma.com

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, regulatory incentives, the development of new business opportunities, and projected costs, revenue, profits and results operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD
First China Pharmaceutical Group, Inc.
————————————————-
Zhen Jiang Wang
Chairman and CEO

Click here to see all recent news from this company

Filed Under: Hospitals and Health Systems, Prescription Drugs and Pharmacy

Biotechnology Firm ImmuneWorks Begins National Clinical Trial for New Idiopathic Pulmonary Fibrosis (IPF) Treatment

Posted on October 19, 2010 Written by Editor

SOURCE: ImmuneWorks

INDIANAPOLIS, IN–(Marketwire – October 19, 2010) –  ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound.

Eight leading academic research universities will conduct the IPF clinical trial: Indiana University, Medical University of South Carolina, Ohio State University, University of Alabama-Birmingham, University of Chicago, University of Louisville, University of Michigan and University of Vermont.

“We are pleased to move forward into clinical investigation of our purified Type V collagen solution in patients suffering from IPF,” said ImmuneWorks Chief Scientific Officer David S. Wilkes, M.D. “This clinical trial is important to study the safety of this naturally derived protein and investigate its ability to influence the ongoing immune response in IPF patients.”

To promote the clinical trial and recruit participants across the eight cities, ImmuneWorks partnered with Indianapolis-based Synergy Marketing Group to develop a new website and conduct search engine optimization (SEO) to reach IPF patients and their physicians, friends and family members in Indianapolis; Chicago; Louisville, Ky.; Ann Arbor, Mich.; Birmingham, Ala.; Charleston, S.C.; Burlington, Vt.; and Columbus, Ohio. The new website is www.ImmuneWorks.com.

ImmuneWorks has been conducting research and development of treatments for serious autoimmune lung diseases for the last five years. Over that time, the company attracted the attention of several key investors, raising nearly $4 million. This funding came from groups including Indiana’s 21st Century Research & Technology Fund, BioCrossroads’ Indiana Seed Fund and the IU Medical Group Foundation.

IPF is a devastating lung disease that is progressive and generally fatal. An estimated 128,000 persons in the United States suffer from IPF, with 48,000 new persons diagnosed annually and 40,000 patients dying from the disease each year (source: Coalition for Pulmonary Fibrosis). The number of deaths annually is the same as breast cancer and greater than other cancers such as multiple myeloma. Currently no FDA-approved medicines exist for IPF in the United States or Europe.

About ImmuneWorks
Headquartered in Indianapolis, ImmuneWorks was formed in 2006 to develop and commercialize treatments for serious autoimmune diseases of the lung. Led by founders David Wilkes, MD; Michael Klemsz, PhD; Ronald Meeusen, PhD; and President and CEO Wade Lange, the company has made pioneering scientific discoveries that ImmuneWorks is developing as novel therapies and diagnostic products for idiopathic pulmonary fibrosis (IPF) and lung transplantation. In November 2009, the U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity to ImmuneWorks’ lead compound, IW001, a purified bovine Type V Collagen oral solution. In June 2010, the U.S. FDA granted ImmuneWorks approval to begin clinical trials on the compound. Now, in collaboration with Lung Rx, LLC, a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), ImmuneWorks is conducting clinical trials among IPF patients to test the effects of its new drug candidate. For more information about the company, visit the new website at www.ImmuneWorks.com.

Filed Under: Hospitals and Health Systems

Vanguard Health Systems, Inc. Invites You to Join Its 2011 First Quarter Earnings Conference Call/Webcast

Posted on October 18, 2010 Written by Editor

SOURCE: Vanguard Health Systems

NASHVILLE, TN–(Marketwire – October 18, 2010) –  In conjunction with Vanguard Health Systems, Inc.’s 2011 First Quarter Earnings press release, you are invited to listen to its conference call that will be broadcast live over the Internet with senior management of Vanguard discussing the operating results.

WHAT:

Vanguard Health Systems, Inc.’s 2011 First Quarter Earnings Conference Call on the Web

WHEN: 

Tuesday, November 9, 2010 at 11:00 a.m. Eastern time

WHERE:

http://www.vanguardhealth.com or
http://www.visualwebcaster.com/event.asp?id=73288

HOW: 

Live over the Internet — Simply log on to the web at one of the addresses above. If you connect through www.vanguardhealth.com, select the “Latest News” link on the Investor Relations page.

Vanguard Health Systems, Inc. will release its 2011 first quarter operating results on Monday, November 8, 2010, after 4:00 p.m. Eastern time. The Company’s earnings press release will be posted under the “Latest News” link on the Investor Relations page of the Company’s web site www.vanguardhealth.com.

Vanguard Health Systems, Inc. owns and operates 18 acute care hospitals and complementary facilities and services in Chicago, Illinois; Phoenix, Arizona; San Antonio, Texas and Massachusetts.

If you are unable to participate during the live Webcast, the call will be archived on our web site www.vanguardhealth.com. To access the replay, click on the “Latest News” link on the Investor Relations page of our web site.

Contact:
Vanguard Health Systems, Inc.
Gary Willis
Senior Vice President and Chief Accounting Officer
(615) 665-6098

Filed Under: Healthcare Business, Hospitals and Health Systems

CardioComm Solutions, Inc. Confirms No Undisclosed Material Information

Posted on October 18, 2010 Written by Editor

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 18, 2010) – Following today’s trading halt by Investment Industry Regulatory Organization of Canada, CardioComm Solutions, Inc. (TSX VENTURE:EKG) (the “Company”) today confirmed that there is no material information pertaining to the Company which has not been disclosed.

About CardioComm Solutions, Inc.

CardioComm Solutions, Inc. (“CardioComm”) has been a consistent provider of ECG management software solutions in the English speaking world for the past 21 years. Its products are marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm is ISO 13485 certified and its products have been cleared for sale in the United States, Canada and the European Union. CardioComm’s competitive advantage is built upon 2 ECG patents, a unique FDA approved ECG analysis algorithm, a world class ECG (signal) viewer and a back-end ECG data management control system. CardioComm’s technology enables the recording, transfer, viewing, analyzing, reporting and storing of electrocardiograms (EKGs) over a global virtual healthcare network by physicians for the diagnosis and management of cardiac patients. CardioComm provides an ECG management solution which complements the majority of the world’s cardiac event monitors, including those intended for the home and tele-health market. CardioComm products are sold worldwide to hospitals, call centers and physicians offices through a combination of its external distribution network and its North American based sales team.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Anatoly Langer, Chairman of the Board

Filed Under: Hospitals and Health Systems

Enclarity ProviderPoint Web Services Delivers Automated, Transactional Provider Record Updates in Real-Time

Posted on October 18, 2010 Written by Editor

SOURCE: Enclarity Inc.

Solutions Save Healthcare Insurance Payers Hundreds of Thousands of Dollars in Wasted Operations Expenses

ALISO VIEJO, CA–(Marketwire – October 18, 2010) –  Enclarity Inc., a leading healthcare information solutions company, today announced the addition of ProviderPoint® Web Services to its portfolio of hosted solutions. ProviderPoint Web Services gives payers an additional option for updating individual provider records in real-time. This Software as a Service (SaaS) solution uses a secure connection between the payer’s and Enclarity’s servers to automatically update one or more records at a time.

“Typically, a health insurance payer submits provider records to Enclarity for data cleaning and augmentation via a regularly scheduled batch process,” said Stephanie Rose-Belcher, vice president of payer solutions, Enclarity. “Using ProviderPoint Web Services, we now can update records on the fly. With our newest solution, customers are able to save time, money and get updates at the speed of their business.”

How it Works
The payer generates a provider output record that needs verification, augmentation and/or correction, and sends the data through Enclarity’s web service technology for processing. Enclarity ProviderPoint processes the record as soon as it is received, and the updated information is returned within seconds to the client’s system. Then, the client’s system applies the verified, corrected data along with augmentation of additional elements to the provider record. To assure speed and quality, Enclarity ProviderPoint Web Services uses system-to-system processing featuring industry-standard Simple Object Access Protocol (SOAP) message that can be uploaded into any application.

For more information about Enclarity ProviderPoint Web Services, listen to our latest podcast or visit our solution page at http://www.enclarity.com/ppws.php.

About Enclarity
Enclarity® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Contacts
Company:
Brian Teeter
Enclarity, Inc.
949-614-8115
Email Contact

Media:
Theresa Dreike
Remarx Media Inc.
714-706-0433 ext. 102
Email Contact

Click here to see all recent news from this company

Filed Under: Hospitals and Health Systems

Shareable Ink Announces Launch of Shareable Ink Analytics for Anesthesia

Posted on October 18, 2010 Written by Editor

SOURCE: Shareable Ink

Business Intelligence Module Provides Previously Inaccessible Insight Into Anesthesia Operations

BOSTON, MA–(Marketwire – October 18, 2010) –  Shareable Ink, the leading provider of enterprise?grade digital pen and paper applications for healthcare, today announced the general availability of its newest solution, Shareable Ink Analytics™ for Anesthesia. The business intelligence module is a valuable extension of Shareable Ink Anesthesia Record™ that automatically extracts clinical, quality, and efficiency?related data from paper anesthesia records. Real?time access to information helps improve outcomes and operations.

Shareable Ink Analytics enables hospitals and groups to analyze 100 percent of charts without labor?intensive manual chart reviews and data extraction. The new solution incorporates dashboards and drill?down reports for a variety of clinical and administrative metrics, including Surgical Care Improvement Project (SCIP) measures, anesthesia turnover times, and on?time case starts. Managers can easily pinpoint areas of improvement and compare performance across facilities and providers by viewing increasingly granular data: from the health system level to individual outliers and cases of interest.

“More than 90 percent of anesthesia recordkeeping is paper?based. As a result, operational data has been traditionally difficult, if not impossible, to aggregate and understand,” said Stephen S. Hau, President and CEO of Shareable Ink. “The Shareable Ink approach enables anesthesia providers to continue their familiar documentation method, while providing all the analytical benefits of electronic data output.”

“With 360 providers in 28 different hospitals and ASCs, Shareable Ink Analytics gives us the ability to instantly review, report, and manage real-time performance,” said Brian Woods, MD, Chief Medical Officer of NorthStar Anesthesia. “From patient clinical outcome measures to OR throughput efficiency assessments, we can now know exactly how we are doing at the enterprise, facility, and individual provider level.”

Shareable Ink Analytics will be featured at the American Society of Anesthesiologists’ Annual Meeting — ANESTHESIOLOGY 2010 — in San Diego from October 16 through October 20. To learn more, please stop by the Shareable Ink booth (#3930).

About Shareable Ink
Shareable Ink helps healthcare organizations of all sizes transition to electronic health records without disruption to workflow or burdensome IT projects. Its software platform incorporates enterprise?grade digital pen and paper technology featuring Anoto functionality. Shareable Ink enables clinicians to continue documenting in the fastest, most natural manner, while populating the EHR with discrete data, as if typed with a keyboard. Built?in analytics give hospitals and practices insight into their operations — from a clinical, quality and efficiency standpoint — all previously inaccessible from traditional paper records. For additional information, visit www.shareableink.com.

Media Contacts:
Suzanne Cogan
Vice President of Sales & Marketing for Shareable Ink
877?572?7423 x802
Email Contact

Filed Under: Hospitals and Health Systems

Omni Bio Announces First Infusion in Phase I/II Clinical Trial of Alpha-1 Antitrypsin in Recently Diagnosed Diabetic Patients

Posted on October 18, 2010 Written by Editor

SOURCE: Omni Bio Pharmaceutical, Inc.

Treatment Commences at Barbara Davis Center for Childhood Diabetes at University of Colorado Denver Anschutz Medical Campus

DENVER, CO–(Marketwire – October 18, 2010) –  Omni Bio Pharmaceutical, Inc. (“Omni Bio”) (OTCBB: OMBP) today announced that the first patient has been infused in its FDA-cleared Phase I/II human clinical trial of Alpha-1 antitrypsin (“AAT”) in recently diagnosed Type 1 diabetics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus.

The Phase I/II clinical trial is evaluating the potential of AAT to halt or reduce the deterioration of islet beta cells that causes Type 1 diabetes. While Type 1 diabetics will experience islet beta cell destruction, the trial evaluates whether AAT treatment may help stop the course of disease in newly diagnosed diabetics who may have remaining islet beta cells.

AAT is an FDA-approved, off-patent drug with an almost 20-year safety track record as an approved treatment in the approximately $400 million market for emphysema in AAT deficient patients. Omni Bio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market.

Dr. Charles A. Dinarello, Acting Chief Executive Officer of Omni Bio, stated, “Following promising preclinical evidence of AAT in Type 1 diabetes, we filed with the FDA to move right into a Phase I/II clinical trial in newly diagnosed Type 1 diabetic patients. We are encouraged by the agency’s clearance to advance from the preclinical stage into actual patients, and the initial patient infusion is a major milestone for Omni Bio. If AAT is effective in disrupting the deterioration of the islet beta cells, we believe that we may be able to expedite our time to market in Type 1 diabetes, given the significance of the unmet medical need and the supportive safety track record of AAT in its currently approved indication.”

Dr. Dinarello continued, “Type 1 diabetes is a large and attractive market for Omni Bio, and we believe that our method of use patent applications surrounding AAT further position us to capitalize on this opportunity to deliver shareholder value while improving treatment for up to 20,000 Type 1 diabetics diagnosed in the U.S. each year.”

About the Phase I/II Trial
The FDA-cleared Phase I/II human clinical trial of AAT in recently diagnosed Type 1 diabetics is underway at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus. Patients will receive an eight-week treatment course of AAT infusions, followed by two years of monitoring. Targeted enrollment is initially 15 patients, and may be expanded to up to 50 patients pending positive data in critical measurements.

About AAT in Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system attacks insulin-producing beta cells in the pancreas, which are necessary for the body to maintain proper blood glucose levels. Not all beta cells are typically destroyed at the time of diagnosis, and between 15-40% remain healthy and able to produce insulin. Preserving these remaining beta cells is the goal of AAT therapy in Type 1 diabetics, as their ability to naturally produce even small amounts of insulin can improve blood sugar control, simplify daily management of diabetes, and reduce the risk of long term complications.

About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio’s core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver (“UCD”) and a privately held corporation surrounding the broader therapeutic potential of currently marketed therapies. One of Omni Bio’s lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, biohazards, diabetes and transplant rejection.

Omni Bio is led by Acting CEO Dr. Charles Dinarello, Professor of Medicine in the Division of Infectious Diseases at UCD. Dr. Dinarello is considered a founding father of cytokine biology. For additional information, please visit www.omnibiopharma.com.

Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements that reflect management’s current views and expectations with respect to future events, including the clinical trial. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to the business risks disclosed in our SEC filings, especially the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Edward C. Larkin
Chief Operating Officer
Omni Bio Pharmaceutical, Inc.
720-488-4708

Sara Pellegrino
The Ruth Group
646-536-7002
[email protected]

Ashleigh Barreto (investors)
The Ruth Group
646-536-7028
[email protected]

Filed Under: Hospitals and Health Systems, Prescription Drugs and Pharmacy

Get a Stronger, Whiter Smile

Posted on October 18, 2010 Written by Editor

SOURCE: Arm & Hammer

MISSION, KS–(Marketwire – October 18, 2010) –  (Family Features) Tooth enamel is the hard, outer layer of the tooth that helps protect the tooth from extreme temperatures and the erosive effects of acids.

At times, enamel gets stained and weakened by things you consume such as coffee, tea, fruit juice, soda, wine or cigarettes. Fortunately, there are things you can do to help keep your smile white and your enamel strong.

  • Floss and brush daily with a fluoride toothpaste.
  • See a dentist every six months for a cleaning and checkup.
  • Reduce your intake of highly acidic foods and drinks or rinse with clear water after eating or drinking these things.

Now, Arm & Hammer offers a way to whiten your teeth and strengthen your enamel conveniently and inexpensively. New Arm & Hammer Whitening Booster Plus Enamel Strengthening is designed to provide safe, effective whitening and enamel strengthening without adding an extra step to your oral-care routine. Simply apply over your favorite fluoride toothpaste and brush as normal. Featuring a peroxide formula with Liquid Calcium, this provides teeth with daily whitening and enamel strengthening when used as directed.

Taking good care of your teeth with healthy habits and easy-to-maintain routines will help keep your smile strong and vibrant.

Filed Under: Hospitals and Health Systems

Carl Zeiss Meditec Introduces New Innovations: ‘Creating What’s to Come’ at AAO 2010

Posted on October 16, 2010 Written by Editor

SOURCE: Carl Zeiss Meditec

Featured Products Include the FORUMTM Glaucoma WorkplaceTM and the VISULAS 532s VITE Laser System; New Indications Cleared for the VisuMax® Femtosecond Laser

CHICAGO, IL–(Marketwire – October 16, 2010) –  AAO Booth #1408 — Carl Zeiss Meditec today unveiled its newest product innovations at the 2010 American Academy of Ophthalmology annual meeting in Chicago. Powered by the FORUM Ophthalmic Data Management System, the new Glaucoma Workplace features FORUM HFA-Cirrus Combined Report (CR™), the world’s first commercially available OCT and visual field integration. In addition, new FDA-cleared products commercially available for the first time in the United States will be on display during the exhibition.

The FORUM Glaucoma Workplace

As part of Carl Zeiss Meditec’s ‘Creating What’s to Come’ theme, the FORUM Glaucoma Workplace delivers essential diagnostic technologies, such as perimetry, spectral domain OCT, fundus photography and scanning laser polarimetry, for unprecedented clinical utility and paperless workflow.

The FORUM Glaucoma Workplace adds a new diagnostic assessment feature — HFA-Cirrus Combined Report — the industry’s first integration of OCT and visual field diagnostic analysis. By combining data from the gold-standard Humphrey® Field Analyzer (HFA™) and Cirrus™ HD-OCT, this FORUM Combined Report provides structure and function status at-a-glance to help doctors make time-saving clinical assessments. This one-page digital snapshot delivers key patient exam information at the point-of-care for both right and left eyes of visual function, RNFL and optic nerve analysis.

“Clinical assessment of glaucoma patients, or particularly patients who have suspect glaucoma, requires assessment of visual function test results and structural parameters comparing both diagnostic modalities in each eye,” said Anders Heijl, MD, PhD, Professor and Chairman, Department of Ophthalmology, University of Lund, Sweden. “Automatically providing structural OCT and visual field data in a single combined on-screen report will save time and facilitate such comparisons. This type of development is important for the quality of clinical decision-making in routine glaucoma care.”

“FORUM’s Glaucoma Workplace and the new HFA-Cirrus Combined Report is a big step forward, and I am excited about the potential of this unique new capability,” said Michael S. Jacobs, MD, of Athens Eye Associates, Athens, GA. “Having OCT and perimetry data available in a single format will allow me to perform a more focused exam and ultimately to spend more time making the decisions that only I can make.”

With an estimated 25,000 Humphrey Field Analyzer II-i perimetry systems and approximately 6,000 Cirrus HD-OCT platforms in use worldwide, Carl Zeiss Meditec customers with both platforms can seamlessly integrate FORUM Glaucoma Workplace and the Combined Report into their practice. In addition, key ZEISS diagnostic instruments sold today are FORUM ready and include DICOM Gateway software and a DICOM Gateway license.*

New FDA-Cleared Products

Also being introduced at this year’s AAO meeting is the VISULAS 532s VITE photocoagulator which recently received marketing clearance from the U.S. Food and Drug Administration (FDA). The new keratoplasty indication for the VisuMax® Femtosecond Laser has also been granted FDA clearance, which is expected to significantly expand the product’s treatment range. 

  • VISULAS 532s VITE — This unique photocoagulation laser features variable and interactive multi-spot treatment cascades, giving ophthalmologists the greatest choice of treatment options to enhance therapeutic workflow and patient comfort during retinal photocoagulation procedures. Based on the concept of flexible treatment multi-spot cascades, linear, circular and customized coagulation strategies can be pursued in addition to traditional single-spot photocoagulation.

  • Keratoplasty Application for the VisuMax® Femtosecond Laser — The VisuMax Femtosecond Laser has received clearance from the U.S. FDA to perform lamellar resection of the cornea, lamellar keratoplasty, penetrating keratoplasty and corneal harvesting procedures. With a fast repetition rate of 500 kHz, the VisuMax delivers highly reproducible incisions with optimized surgical workflow.

“We are pleased to deliver a new suite of innovations that represents our philosophy of ‘Creating What’s to Come’ at this year’s AAO meeting,” said Ludwin Monz, CEO of Carl Zeiss Meditec. “Evolving from the FORUM Ophthalmic Data Management System that we introduced just one year ago, we now offer the Glaucoma Workplace and FORUM Combined Report, each of which will deliver time-saving and workflow advantages to ophthalmic practices worldwide. In addition, we are pleased to introduce new FDA-cleared therapeutic lasers that span refractive and retina treatment capabilities, reinforcing our commitment to continually advance our integrated product offerings for the benefit of our customers and their patients.” 

The FORUM Glaucoma Workplace and new FDA-cleared products will be on display at Carl Zeiss Meditec’s booth #1408 at McCormick Place in Chicago, IL. In addition, meeting delegates are invited to attend the Company-sponsored evening event, “A Vision For Your Future…Today” on Saturday, October 16, 2010 at the River East Art Center. Dual education symposia: “OCT Breakfast Conference with the Experts,” and the “Innovations in Refractive and Corneal Surgery,” will be held for meeting delegates on Sunday morning, October 17, 2010 at the Palmer House Hilton Hotel.

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies.

The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery, the Company provides innovative visualization solutions. Carl Zeiss Meditec’s medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company’s approximately 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec’s shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets “Medical and Research Solutions,” “Industrial Solutions” and “Lifestyle Products.” Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the Company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.

For further information please visit our website at: www.meditec.zeiss.com

* FORUM-Ready is not available for FDT and Matrix.

Contact:
Eva Sesselmann
Director Group Communications
Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
07745 Jena
Telefon: +49 3641 220-331
Telefax: +49 3641 220-332
Email: Email Contact

Carmen Caricchio
President
CoActive Health Communications
2600 18th Street, Suite 21
San Francisco, CA 94110
Telephone: +415 621-6626
Fax: +415 621-6636
Email: Email Contact

Click here to see all recent news from this company

Filed Under: Healthcare Business, Hospitals and Health Systems

Craig Westin, M.D., Named Sports Medicine Physician for the Joffrey Ballet

Posted on October 15, 2010 Written by Editor

SOURCE: Craig Westin, M.D.

CHICAGO, IL–(Marketwire – October 15, 2010) –   As Chicago’s premier dance company, the Joffrey Ballet kicks off its 2010/2011 season this week, the man in charge of keeping the dancers healthy and meeting any medical needs that may arise is Craig Westin, M.D., of Illinois Bone and Joint Institute and the Chicago Center for Orthopedics (CCO) at Weiss Hospital. Named troupe physician and CCO orthopedic surgeon for the Joffrey Ballet this year, Dr. Westin brings more than 26 years of experience working with professional performers and athletes to the dancers’ care. Whether pre-season physician examinations, regular clinics with the dancers at the Joffrey studios, or an emergency consultation at Weiss Hospital, these healthcare services are an essential part of a successful dance season.

As an orthopedic resident at Harvard, Dr. Westin began treating dancers when he helped cover the Boston Ballet. He continued with Ballet West in Salt Lake City, where he also served as medical director of the Snowbird Ski Clinic. After 17 years at Snowbird and the 2002 Winter Olympics in Salt Lake City, Dr. Westin moved to Chicago. Over the past 15 years, Dr. Westin has been a physician to the U.S. and Olympic Figure Skating team and traveled with them to Europe, China and Russia. He is also the personal orthopedic surgeon for Olympic Figure Skating Silver Medalist Sasha Cohen. Specializing in sports medicine with a particular focus on the knee and shoulder, Dr. Westin uses minimally invasive arthroscopic techniques for outpatient knee and shoulder repairs. As well as being a certified Carticel surgeon for cartilage repair and restoration, he has special expertise in reconstruction of ACL tears and kneecap problems.

Dr. Westin uses many non-operative treatments to help his patients recover. Treatments like physical therapy, injections, braces, orthotics and other rehabilitation techniques can provide dramatic improvement for many conditions. “What we learn from treating these gifted and highly motivated performers can often be applied to the rest of us. We all have the same body parts, they can just use theirs a lot better,” says Westin.

“I’m honored to be named the sports medicine physician for the Joffrey Ballet. I have a deep appreciation for these athletes’ need for top care and am pleased that I can play a role in keeping them healthy and performing. It’s very satisfying to see them on stage able to use their bodies for inspiring expression,” added Dr. Westin.

The Sports Medicine Experts at Weiss
CCO orthopedic surgeons and sports medicine physicians — with affiliations at Chicago’s academic and research facilities, including the University of Chicago, the University of Illinois and Loyola University Chicago — treat Joffrey Ballet dancers and other athletes to ensure their long-term health and viability on and off the stage or athletic fields. CCO brings a balance of preventive care, individual athlete/patient understanding and leading-edge techniques.

Contact:
Brooke Fochler
Winger Marketing
312/494-0422
[email protected]

Filed Under: Hospitals and Health Systems

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 22
  • Next Page »

Search Our Site

Categories

  • Blue Cross Blue Shield
  • Health Insurance Companies
  • Health Insurance Coverage
  • Health Technology and AI
  • Healthcare Business
  • Healthcare Policy and Law
  • Hospitals and Health Systems
  • Medicaid and CHIP
  • Medicare
  • Prescription Drugs and Pharmacy
  • Public Health and Research
  • Senior Care

Entity Map

Disclaimer

All content on Health Plan News and information provided on this website is for informational purposes only and is not intended as a substitute for advice from your physician or other healthcare professional. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. Always consult with a healthcare professional before starting any diet, exercise, or supplementation program, before taking any medication, or if you have or suspect you might have a health problem.

Copyright © 2026 - Privacy Policy - Terms of Use - Disclaimer